



# Article Effects of Probiotic Supplementation on Immune and Inflammatory Markers in Athletes: A Meta-Analysis of Randomized Clinical Trials

Yi-Ting Guo <sup>1,2,†</sup>, Yu-Ching Peng <sup>1,2,†</sup>, Hsin-Yen Yen <sup>3,†</sup>, Jeng-Cheng Wu <sup>2,4,5,6,7,\*</sup> and Wen-Hsuan Hou <sup>2,3,8,9,10,\*</sup>

- <sup>1</sup> School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
- <sup>2</sup> Department of Education, Taipei Medical University Hospital, Taipei 110, Taiwan
- <sup>3</sup> School of Gerontology and Long-Term Care, College of Nursing, Taipei Medical University, Taipei 110, Taiwan <sup>4</sup> Department of Urology School of Medicine, College of Medicine, Taipei Medical University.
- <sup>4</sup> Department of Urology, School of Medicine, College of Medicine, Taipei Medical University,
- Taipei 110, Taiwan TMU Research Center of Urology and Kidney, Taipei Medical University, Taipei 110, Taiwan
- <sup>5</sup> TMU Research Center of Urology and Kidney, Taipei Medical University, Taipei 110,
   <sup>6</sup> Department of Urology, Taipei Medical University Hospital, Taipei 110, Taiwan
- <sup>7</sup> Department of Health Promotion and Health Education, College of Education, National Taiwan Normal University, Taipei 106, Taiwan
- <sup>8</sup> College of Medicine, National Cheng Kung University, Tainan 701, Taiwan
- <sup>9</sup> Department of Physical Medicine and Rehabilitation & Geriatrics and Gerontology, Taipei Medical University Hospital, Taipei 110, Taiwan
- <sup>10</sup> Cochrane Taiwan, Taipei 110, Taiwan
- \* Correspondence: 883003@h.tmu.edu.tw (J.-C.W.); houwh@tmu.edu.tw (W.-H.H.); Tel.: +886-2-27372181 (ext. 8265) (J.-C.W.); +886-2-27361661 (ext. 6311) (W.-H.H.)
- + These authors contributed equally to this work.

Abstract: Background and Objectives: Probiotic supplementation can prevent and alleviate gastrointestinal and respiratory tract infections in healthy individuals. Markers released from the site of inflammation are involved in the response to infection or tissue injury. Therefore, we measured the pre-exercise and postexercise levels of inflammation-related markers-tumor necrosis factor (TNF)- $\alpha$ , interleukin (IL)-6, IL-8, IL-10, interferon (IFN)- $\gamma$ , salivary immunoglobulin A (IgA), IL-1 $\beta$ , IL-2, IL-4, and C-reactive protein (CRP)-in probiotic versus placebo groups to investigate the effects of probiotics on these markers in athletes. Probiotics contained multiple species (e.g., Bacillus subtilis, Bifidobacterium bifidum, etc.). Materials and Methods: We performed a systematic search for studies published until May 2022 and included nine randomized clinical trials. Reporting followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses guideline. Fixed-effects meta-analyses and sensitivity analyses were performed. Subgroup analyses were conducted on the basis of the period of probiotic intervention and timing of postassessment blood sampling. Results: The levels of IFN- $\gamma$  and salivary IgA exhibited a significant positive change, whereas those of TNF- $\alpha$ and IL-10 demonstrated a negative change in the probiotic group. The subgroup analysis revealed that the probiotic group exhibited significant negative changes in TNF- $\alpha$  and IL-10 levels in the shorter intervention period. For the subgroup based on the timing of postassessment blood sampling, the subgroup whose blood sample collection was delayed to at least the next day of exercise exhibited significant negative changes in their TNF- $\alpha$  and IL-10 levels. The subgroups whose blood samples were collected immediately after exercise demonstrated negative changes in their TNF- $\alpha$ , IL-8, and IL-10 levels. Conclusions: Probiotic supplementation resulted in significant positive changes in the IFN- $\gamma$  and salivary IgA levels and negative changes in the IL-10 and TNF- $\alpha$  levels. No significant changes in the IL-1β, IL-2, IL-4, IL-6, IL-8, or CRP levels were observed after probiotic use in athletes.

Keywords: athletes; inflammation-related markers; meta-analysis; probiotics



Citation: Guo, Y.-T.; Peng, Y.-C.; Yen, H.-Y.; Wu, J.-C.; Hou, W.-H. Effects of Probiotic Supplementation on Immune and Inflammatory Markers in Athletes: A Meta-Analysis of Randomized Clinical Trials. *Medicina* 2022, *58*, 1188. https://doi.org/ 10.3390/medicina58091188

Academic Editor: Jose Antonio de Paz

Received: 5 August 2022 Accepted: 25 August 2022 Published: 31 August 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

# 1. Introduction

Individuals who engage in strenuous exercise are more likely to experience upper respiratory tract and gastrointestinal illness, especially diarrhea, during heavy training and competitions such as a marathon [1-4]. Strenuous exercise causes immunosuppression by reducing the function of immune cells, thus increasing susceptibility to viral infection [5,6]. Gastrointestinal illness is typically characterized by belching, bloating, flatulence, side stitch, abdominal cramps, vomiting, diarrhea, the urge to defecate during exercise, nausea, and loss of appetite [7,8]. Respiratory illness is often characterized by throat soreness, sneezing, a blocked or runny nose, and cough [8]. Athletes may be more at risk of infection during heavy training [9–11], possibly because of the suppression of mucosal immunity, which, in turn, increases susceptibility to gastrointestinal and respiratory illness [2], or alternatively because of the combined effects of small changes in several immune parameters [12]. Therefore, elite athletes are required to reduce the risk of infection and shortly recover from susceptibility to gastrointestinal and respiratory symptoms. Evidence increasingly indicates that probiotic supplementation can prevent and alleviate gastrointestinal and respiratory tract infections (common cold and influenza) in healthy individuals and have an influence on body defense [13,14].

The term probiotic is used for products that deliver the required number of viable cells of bacterial strains that can benefit the health of a host by changing the composition of the host's gut microbiota [15–18]. Probiotics mainly serve as supplements [19] containing multiple species (e.g., *Bacillus subtilis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium lactis, Bifidobacterium longum* ES1, *Bifidobacterium animalis* subsp. *lactis, Enterococcus faecium* W54, *Lactobacillus acidophilus, Lactobacillus brevis* W63, *Lactobacillus casei, Lactobacillus plantarum*, *Lactobacillus helveticus, Lactococcus lactis, Lactobacillus paracasei, Lactobacillus plantarum* TWK10, *Lactobacillus rhamnosus* GG, *Lactobacillus salivarius*, and *Streptococcus thermophilus*) and are usually prepared in the form of capsules [8,20–23], powder sticks [24,25], sachets [26], and fermented drinks [27].

Cytokines, which are small peptides facilitating the influx of lymphocytes, neutrophils, monocytes, and other cells, are released from sites of inflammation and are involved in the response to infections or tissue injury [28–30]. Probiotics have been reported to modulate inflammation and systemic immune responses in experimental animals, such as by affecting defense mechanisms and the release of several cytokines (e.g., tumor necrosis factor (TNF)- $\alpha$  and interferon (IFN)- $\gamma$ ) [31,32]. Probiotics can also improve several inflammatory and oxidative stress biomarkers [33]. The balance between proinflammatory and anti-inflammatory cytokines, which regulate immune cell homeostasis, is dynamic and ever-shifting in the human immune system [34,35]. The cytokines initially involved in a cytokine storm include TNF- $\alpha$ , interleukin (IL)-1 $\beta$ , IL-6, and IL-10 [36]. High-intensity long-duration exercise can lead to higher levels of inflammatory mediators, including IL-1 $\beta$ , IL-6, and TNF- $\alpha$ , and thus increase the risk of injury and chronic inflammation [37,38]. IL-2 is considered a key growth and death factor for antigen-activated T lymphocytes [39]. IL-4 is associated with type 2 inflammation, which is related to parasite infection and chronic diseases, including asthma and atopic dermatitis [40]. A systematic review and meta-analysis demonstrated an elevation in IL-1 $\beta$ , IL-8, IL-10, and TNF- $\alpha$  levels; a reduction in IL-2 and IFN- $\gamma$  levels; and no change in the IL-4 level after long-distance running [41]. However, TNF- $\alpha$  plays a crucial role in several physiological and pathological conditions related to its action in inflammation and leukocyte movement [42]. IL-6 is a cytokine present in circulation during exercise. A study reported that after a person took probiotics, their IL-6 level increased exponentially in response to exercise and declined during the postexercise period [28]. Salivary immunoglobulin A (IgA) as a biomarker is associated with the incidence of infection; its low level or a substantial transitory decline is related to an increase in the incidence of upper respiratory tract diseases [43]. Probiotics increased mucosal salivary IFN- $\gamma$ , IgA1, and IgA2 levels in healthy adults [44]. However, evidence from clinical trials regarding the effects of probiotic supplementation on immune and inflammatory markers in athletes is lacking. Scholars have reported inconsistent results. Several studies have

reported no significant change after probiotic supplementation [20,23,25]. By contrast, some studies demonstrated that the TNF- $\alpha$  level was lower in both sexes after probiotic supplementation [22] and observed a significantly decreased IL-6 level and increased IL-10 level in a probiotic group compared with a placebo group [21]. Moreover, probiotic supplementation attenuated acute exercise-induced changes in both anti-inflammatory and proinflammatory cytokines (IL-6, IL-8, IL-10, IFN- $\gamma$ , and TNF- $\alpha$ ) in male and female athletes [8,45].

This study determined the effect of probiotics on inflammation-related markers (TNF- $\alpha$ , IL-6, IL-8, IL-10, IFN- $\gamma$ , salivary IgA, IL-1 $\beta$ , IL-2, IL-4, and C-reactive protein (CRP)) in athletes by examining the levels of these markers before and after exercise in probiotic and placebo groups.

# 2. Materials and Methods

#### 2.1. Data Sources

The review protocol was prospectively registered on PROSPERO (CRD42022302897), and our findings are reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline. A research librarian systematically searched for relevant studies in PubMed, Cochrane Library, CEPS, and Embase from the inception to 12 May 2022. Citations were managed using Endnote version 20.1 (Clarivate Corp., Philadelphia, PA, USA; London, UK).

## 2.2. Eligibility Criteria

Clinical trials that included healthy human athletes involved in any sport and of any sex, age range, and race and that provided original pre-exercise and postexercise blood data were eligible. We considered interventions involving the administration of probiotics that contained alone or multiple mixed species and were prepared in all forms, including capsules or sticks. Studies that administered to their control group a placebo that was manufactured to be identical to the probiotics in packaging, encapsulation, and taste were eligible for inclusion.

We excluded clinical trials that met one of the following criteria: (1) did not include athletes, (2) were designed as nonparallel randomized clinical trials (RCTs), (3) had only a single arm, (4) did not examine inflammation-related markers, (5) had an intervention period of <14 days, (6) included patients with diseases as the study population, and (7) combined other supplements or medication in their intervention. Furthermore, we excluded studies that measured inflammation-related markers only after the probiotic supplementation.

## 2.3. Data Selection and Extraction

One researcher (YTG) searched for relevant RCTs published in the PubMed, Embase, Cochrane Library, and Chinese Electronic Periodical Services (CEPS) databases from their inception until May 2022. Another researcher (YCP) evaluated the selected RCTs. The researchers were blinded to each other's decisions. The outcomes were reviewed by two researchers. All retrieved abstracts, studies, and citations were reviewed. The decisions of the two researchers were compared, and if the two reviewers could not reach a consensus, any disagreements were resolved through discussion with a third researcher (WHH).

The two researchers (YTG and YCP) independently extracted data. If data were only presented graphically, values were estimated from figures by using WebPlotDigitizer version 4.5 [46]. Finally, data were analyzed using RevMan 5.4.1 (Cochrane Collaboration, Oxford, UK).

## 2.4. Outcomes

The pre-exercise and postexercise blood levels of inflammation-related markers in the probiotic and placebo groups were measured to determine the effect of probiotics. To perform a meta-analysis, we excluded the outcomes of specific cytokines, which were only measured in one RCT.

# 2.5. Assessment of Risk of Bias

The two reviewers (YTG and YCP) independently determined the risk of bias by using the revised Cochrane risk-of-bias tool for randomized trials, version 2 (RoB 2.0) (Bristol, England) in accordance with the *Cochrane Handbook for Systematic Reviews of Interventions, Version 5.2.12*; this tool measures the potential for bias arising from five domains: the randomization process, deviation from the intended intervention, missing outcome data, outcome measurement, and selection of reported results. Possible responses were "yes", "probably yes", "probably no", "no", and "no information". Domains were evaluated as having either low or high risk of bias or some concerns [47]. Assignment or intention to treat was the outcome of interest. Disagreement was resolved through discussion with the third author (WHH).

## 2.6. Statistical Analysis


All analyses were performed using the fixed-effects model with Review Manager version 5.4.1 (Cochrane Collaboration, Oxford, UK), which includes MetaView for presenting graphs and figures. The mean difference and 95% confidence interval (CI) were calculated for each trial and are presented in a forest plot.

To assess heterogeneity, I<sup>2</sup> statistics were calculated. An I<sup>2</sup> greater than 50% represents substantial heterogeneity. The potential risk of small-study bias was visually examined by generating funnel plots [48]. Statistical significance was set at a *p* value of <0.05, except for publication bias, where a *p* value of <0.10 was considered. Sensitivity analysis was performed by removing outlier studies—those with CIs that did not overlap with the CI of the pooled effect [49]. If I<sup>2</sup> was >50%, subgroup analysis was conducted to determine potential factors contributing to the heterogeneity, such as the length of the probiotic intervention (less than 6 weeks vs. more than 6 weeks) and the time of postassessment blood sampling (immediately after exercise vs. delayed to at least the next day of exercise). No further subgroup analysis was performed if an outcome was examined in only two studies. Publication bias was evaluated using Egger's test. The funnel plot we constructed evaluates the pseudo 95% CI against the standard error of evaluations. Owing to heterogeneity, we used the fixed-effect model because when a conventional funnel plot is used to examine publication bias, the plot is assumed to be inaccurate when the number of studies included in the analysis is small [46].

#### 3. Results

## 3.1. Study Selection

Figure 1 presents the PRISMA flowchart of the study screening and selection processes used in this research. Through a literature search, we retrieved relevant publications from PubMed (n = 92), Cochrane Library (n = 37), Embase (n = 41), and CEPS (n = 4). A total of 41 RCTs were retained after the exclusion of 133 duplicate studies. After the titles and abstracts had been screened, we excluded 26 studies and evaluated the eligibility of the remaining 15 studies. After the full-text assessment, we excluded six trials for several reasons (i.e., intervention time being <14 days, adoption of a crossover design, and examination of inflammation-related markers in only one study). A total of nine studies that met the inclusion criteria were included in this systemic review and meta-analysis.



**Figure 1.** Preferred Reporting Items for Systematic Reviews and Meta-Analysis flowchart of the search strategy.

## 3.2. Characteristics of Included Studies

Table 1 summarizes the characteristics of the nine studies that examined ten inflammationrelated markers, namely TNF- $\alpha$ , IL-6, IL-8, IL-10, IFN- $\gamma$ , salivary IgA, IL-1 $\beta$ , IL-2, IL-4, and CRP. A brief description of their main features is provided in the following sections in compliance with the review strategy.

The nine trials were published between 2011 and 2021, and their sample sizes ranged from 13 to 97. A total of 335 participants were included (170 in the probiotic group and 165 in the placebo group). No difference was noted in age or body mass between the groups. The intervention period did vary somewhat among the studies, ranging from 28 to 90 days.

Five of the selected RCTs lasted 4 weeks (30 days) [21,23–26], one RCT lasted 8 weeks [27], and three RCTs lasted from 11 to 12 weeks (90 days) [8,20,22]. Sticks, capsules, sachets, or fermented milk were consumed once or twice per day during the supplementation period. Six RCTs used supplementation capsules containing *B. lactis*, and among them, capsules used in three RCTs also contained *B. longum* ES1. The probiotics in each study contained at least one type of *Bifidobacterium* species or *Lactobacillus* species. The control groups were mainly administered sensorially identical placebo capsules, sticks, or sachets containing excipients only without bacteria.

# 3.3. Inflammatory-Related Markers

Of the nine studies, seven reported the TNF- $\alpha$  level, five reported the IL-6 level, four reported the IL-8 level, five reported the IL-10 level, two reported the IFN- $\gamma$  level, two reported the salivary IgA level, two reported the IL-1 $\beta$  level, two reported the IL-2 level, two reported the IL-4 level, and two reported the CRP level. One study [20] only indicated the differences in these markers after the intervention. Therefore, we determined differences in the levels of these markers by subtracting the preintervention values from the postintervention values.

Source	Publication Date	Country	Sport Type	Species	Assessed Inflammatory Markers	Probiotic Type	Control (Placebo) Type	Male Female Total	Probiotic Control	Probiotic Control	Probiotics	Baseline Assessment Time	Dose ( <sup>16</sup> CFU)	Frequency	Intervention Time	Post- Intervention Assessment Time
West, 2011	2011 April	Australia	Cycling	L. fermentum	IL-6, IL-8, IL-10, IFN-γ, TNF-α	Capsule	Capsule	M: 62 F: 35 T: 97	P: 47 C: 50 T: 97	$\begin{array}{c} P: 35.2 \pm 10.3 \\ C: 36.4 \pm 8.9 \end{array}$	$\begin{array}{c} P: 77.9 \pm 8.4 \\ C: 76.9 \pm 8.2 \end{array}$	Prior to supplement period	1 billion CFU	1 capsule QD	11 weeks	Immediately after a race
Tavares-Silva, 2021	2021 April	Brazil	Running	B. bifidum, B. lactis, L. acidophilus, L. lactis, L. paracasei	IL-2, IL-4, IL-10, TNF-α, salivary IgA	Capsule	Capsule	M: 14 F: 0 T: 14	P: 7 C: 7 T: 14	$\begin{array}{c} P:41.57\pm3.20\\ C:38.28\pm3.09 \end{array}$	$\begin{array}{c} P:71.24\pm 3.55\\ C:78.43\pm 8.40 \end{array}$	Îst day	5 billion CFU	2 g <sup>20</sup> QN	30 days	Immediately after a race
Smarkusz- Zarzecka, 2020	2020 December	Poland	Running	B. bifidum, B. animalis subsp. lactis, L. acidophilus, L. brevis W63, L. lactis, L. salivarius	CRP, TNF-α	Capsule	Capsule	M: 46 F: 20 T: 66	P: 34 C: 32 T: 66	$\begin{array}{c} P{:}39.35\pm8.23\\ C{:}37.62\pm8.82 \end{array}$	P: 72.46 $\pm$ 4.62 C: 78.26 $\pm$ 6.74	Prior to supplement period	2.5 billion CFU	2 capsules BID	90 days	After the supplement period; physical activity was avoided for at least 24 h before the test
Schreiber, 2021	2021 May	Israel	Cycling	B. subtilis, B. lactis, B. longum ES1, E. faecium W54, L. helveticus	IL-6, <sup>10</sup> CRP, TNF- α	Capsule	Capsule	M: 27 F: 0 T: 27	P: 11 C: 16 T: 27	P: $25.9 \pm 4.6$ C: $29.5 \pm 6.2$	$\begin{array}{c} P: 71.3 \pm 8.9 \\ C: 72.0 \pm 6.2 \end{array}$	1st day	15 billion CFU	1 capsule QD	90 days	90th day; strenuous activity was avoided for at least 24 h
Quero-Calero, 2022	2022 March	Spain	Soccer	B. lactis, B. longum ES1, L. rhamnosus GG	IL-6, IL-8, TNF- α	Powder stick	Powder stick	M: 13 F: 0 T: 13	P: 7 C: 6 T: 13	$\begin{array}{c} P: 20.6 \pm 1.39 \\ C: 21.9 \pm 2.77 \end{array}$	$\begin{array}{l} P: 70.57 \pm 6.75 \\ C: 73.95 \pm 6.42 \end{array}$	1st day	1 billion CFU	1 #QD	30 days	30th day at 8 a.m.
Quero, 2021	2021 April	Spain	Soccer	B. lactis, B. longum ES1, L. rhamnosus GG	IL-1β, IL-10, salivary IgA	Powder stick	Powder stick	M: 13 F: 0 T: 13	P: 7 C: 6 T: 13	$\begin{array}{c} P: 20.66 \pm 1.39 \\ C: 21.9 \pm 2.77 \end{array}$	$\begin{array}{l} {\rm P:}~70.57\pm 6.75\\ {\rm C:}~73.95\pm 6.42\end{array}$	1st day	1 billion CFU	1 #QD	30 days	30th day at 8 a.m.
Pugh, 2019	2019 July	UK	Running	B. bifidum, B. animalis subsp. lactis, L. acidophilus	IL-6, IL-8, IL-10	Capsule	Capsule	M: 20 F: 4 T: 24	P: 11 C: 9 T: 20	$\begin{array}{c} P: 34.8 \pm 6.9 \\ C: 36.1 \ \pm \ 7.5 \end{array}$	P: 76.5 ± 9.4 C: 73.5 ± 11.3	4 weeks before the marathon and prior to the supplement period	25 billion CFU	1# 19 QDAMPC, 1# on the morning of the race, 1# 2 h before the start	28 days	Immediately after a race
Gleeson, 2011	2011 February	UK	Endurance- based activities	<i>L. casei</i> Shirota	IL-1 β , IL-2, IL-4, IL-6, IL-8, IL-10, IFN-γ, TNF-α, <sup>9</sup> salivary IgA	Fermented drink	Identical in color and taste	M: 54 F: 30 T: 84	P: 32 C: 26 T: 58	$\begin{array}{c} P: 32 \pm 14 \\ C: 25 \pm 9 \end{array}$	P: 71.2 ± 9.9 C: 71.6 ± 10.7	1st day	6.5 billion CFU	1# <sup>18</sup> BID	8 weeks	After 8 weeks and 16 weeks; strenuous activity was avoided for at least 24 h
Batatinha, 2020	2020 November	Brazil	Runners	B. animalis subsp. Lactis L. acidophilus	$ \begin{array}{c} 1 & \text{IL-1 }\beta \ , 2 \\ \text{IL-2, }3 & \text{IL-4, }4 \\ \text{IL-6, }5 & \text{IL-8, }6 \\ \text{IL-10, }7 \\ \text{IFN-}\gamma \ , 8 \\ \text{TNF-}\alpha \end{array} $	Sachets	Sachets	<sup>11</sup> M: 27 12 F: 0 13 T: 27	<sup>14</sup> P: 14 15 C: 13 T: 27	$\begin{array}{l} P: 35.96 \pm 5.81 \\ C: 40.46 \pm 7.79 \end{array}$	P: 79.30 $\pm$ 10.99 C: 72.67 $\pm$ 10.20	1st day	20 billion CFU	1# <sup>17</sup> QD	30 days	1 h after a race

Table 1. Characteristics of	of the studies	included in	the meta-analysis.
-----------------------------	----------------	-------------	--------------------

<sup>1</sup> IL-1β, interleukin-1 beta; <sup>2</sup> IL-2, interleukin-2; <sup>3</sup> IL-4, interleukin-4; <sup>4</sup> IL-6, interleukin-6; <sup>5</sup> IL-8, interleukin-8; <sup>6</sup> IL-10, interleukin-10; <sup>7</sup> IFN-γ, interferon-gamma; <sup>8</sup> TNF-a, tumor necrosis factor-alpha; <sup>9</sup> salivary IgA, salivary immunoglobulin A; <sup>10</sup> CRP, C-reactive protein; <sup>11</sup> M, male; <sup>12</sup> F, female; <sup>13</sup> T, total; <sup>14</sup> P, probiotics; <sup>15</sup> C, control; <sup>16</sup> CFU, colony-forming unit; <sup>17</sup> QD, once a day; <sup>18</sup> BID, twice a day; <sup>19</sup> QDAMPC, once a day after breakfast; <sup>20</sup> QN, once in the night.

The timing of the blood sampling in the baseline and postintervention assessments varied. For the baseline assessment, all the studies collected samples prior to the supplementation period with regular exercising. For the postintervention assessment, two studies collected blood samples at 8 a.m. on the 30th day, three studies collected samples after the supplementation period and ensured that participants did not perform strenuous exercise for at least 24 h before sample collection, one study collected samples 1 h after a race, and

#### 3.4. RoB 2.0 Assessment

three studies collected samples immediately after a race.

RoB 2.0 indicated overall high risk for one study, some concerns for three studies, and low risk for five studies for the outcome of inflammation-related markers. Overall, some concerns were concluded for the differences between the probiotic and placebo groups indicating that fat mass was higher in the probiotic group [26], body fat was significantly higher in the placebo group [20], and the white blood cell count was higher in women in the placebo group [8]. Low risk of bias was determined for the blood sampling outcome. We discovered high risk of attrition bias for one study [21] that excluded one participant due to an outlier and had a >20% loss in the follow-up and another study that excluded the data of four participants due to there being insufficient blood volume to enable analyses and had a 31% loss in the follow-up [27]. Because all nine RCTs reported the blinding of assessors, we considered them to have a low risk of detection bias. Studies reporting that the raw data of outcomes were unadjusted were considered to have low risk of reporting bias. Figure 2 presents the risks of bias of all the included studies in the five domains.




Figure 2. Flowchart of the risk of bias domains.

# 3.5. Overall Effects

The overall effect size for the TNF- $\alpha$  outcome was -0.30 (95% Cl: -0.42, -0.17, p < 0.00001; heterogeneity: chi-square = 31.5, df = 6, p < 0.0001, I<sup>2</sup> = 81%), indicating that the probiotic group exhibited a significant negative change in the TNF- $\alpha$  level compared with the control group (Figure 3). An outlier study was noted [27]. Therefore, a sensitivity analysis was performed by excluding this study for all relevant outcomes.

The effect size for various modes and sites of stimulation is presented in Table 2.

# 3.6. Outcome of TNF- $\alpha$

The effect size of the remaining six RCTs for the TNF- $\alpha$  outcome was -0.29 (95% Cl: -0.42, -0.16, p < 0.00001; heterogeneity: chi-square = 16.48, df = 5, p = 0.006,  $I^2 = 70\%$ ). The probiotic group exhibited a significant negative change in the TNF- $\alpha$  level compared

with the control group in the fixed-effect model (Figure 4a). Because an I<sup>2</sup> value of >50% represents substantial heterogeneity, we performed a subgroup analysis.


	Exp	eriment	al	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
Batatinha 2020	1.4	1.07	12	1.35	1.25	12	1.9%	0.05 [-0.88, 0.98]	+
Gleeson 2011	-14.1	14.39	25	0	9.39	20	0.0%	-14.10 [-21.08, -7.12]	
Quero-Calero 2022	0.1	0.25	7	0.68	0.21	6	26.2%	-0.58 [-0.83, -0.33]	1
Schreiber 2021	-0.02	0.23	11	0.06	0.21	16	56.3%	-0.08 [-0.25, 0.09]	•
Smarkusz-Zarzecka 2020	-1.54	0.87	34	-1.03	1	32	8.0%	-0.51 [-0.96, -0.06]	-
Tavares-Silva 2021	1.1	0.65	7	1.96	0.4	7	5.1%	-0.86 [-1.43, -0.29]	-
West 2011	1.22	2.01	47	1.68	2.09	50	2.5%	-0.46 [-1.28, 0.36]	7
Total (95% CI)			143			143	100.0%	-0.30 [-0.42, -0.17]	1
Heterogeneity: Chi <sup>2</sup> = 31.50	, df = 6 (l	P < 0.00	101); I <sup>z</sup> :	= 81%					-20 -10 0 10 20
Test for overall effect: Z = 4.	54 (P < 0	0.00001	)						-20 -10 0 10 20 Favours [experimental] Favours [control]

**Figure 3.** Outcomes for tumor necrosis factor (TNF)  $-\alpha$ , indicating that the probiotic group exhibited a significant negative change. An outlier study was noted.

		Period of Probio	otic Intervention		ostassessment Sampling
Inflammation- Related Marker	Overall Effect	Shorter Period	Longer Period	Delayed to at Least the Next Day of Exercise	Immediate Assessment after Exercise
TNF-α	-0.29 (-0.42, -0.16)	-0.59 (-0.81, -0.37)	-0.15 (-0.30, 0.01)	-0.26 (-0.40, -0.13)	-0.57 (-0.99, -0.16)
IL-6	0.19 (-0.25, 0.63)	-0.11 (-4.56, 4.34)	0.20 (-0.25, 0.64)	-0.77 (-1.91, 0.37)	0.36 (-0.11, 0.84)
IL-8	-0.57 (-1.33, 0.19)	-1.23 (-2.48, 0.03)	-0.20 (-1.15, 0.75)	-0.17 (-1.11, 0.77)	-1.31 (-2.59, -0.04)
IL-10	-0.1 (-0.19, -0.06)	-0.13 (-0.19, -0.06)	-0.33 (-1.01, 0.35)	-0.12 (-0.19, -0.05)	-0.52 (-0.98, -0.07)
IFN-γ	14.33 (13.76, 14.89)				
IgA	3.57 (0.66, 6.48)				
IL-β	-0.03 (-0.14, 0.08)				
IL-2	-0.04 (-0.38, 0.31)				
IL-4	-0.14 (-1.05, 0.77)				
CRP	-0.69 (-2.51, 1.13)				

 Table 2. Overall effect of inflammation-related markers.

For a shorter intervention period, the probiotic group exhibited a significant negative change in the TNF- $\alpha$  level compared with the control group, with an effect size of -0.59 (95% Cl: -0.81, -0.37, p < 0.00001; heterogeneity: chi-square = 2.70, df = 2, p = 0.26,  $I^2 = 26\%$ ). For a longer intervention period, the probiotic group exhibited a significant change in the TNF- $\alpha$  level compared with the control group, with an effect size of -0.15 (95% Cl: -0.30, 0.01, p = 0.07; heterogeneity: chi-square = 3.62, df = 2, p = 0.16,  $I^2 = 45\%$ ; Figure 5a). In terms of the timing of postintervention blood sampling, the subgroup whose blood sample collection was delayed to at least the next day of exercise demonstrated a significant negative change in the TNF- $\alpha$  level compared with the control group, with an effect size of -0.26 (95% Cl: -0.40, -0.13, p = 0.0001; heterogeneity: chi-square = 11.74, df = 2, p = 0.003,  $I^2 = 83\%$ ). The subgroup whose blood samples were collected immediately after exercise exhibited a significant negative change in the TNF- $\alpha$  level compared with the control group, with an effect size of -0.57 (95% Cl: -0.99, -0.16, p = 0.007; heterogeneity: chi-square = 2.78, df = 2, p = 0.25,  $I^2 = 28\%$ ; Figure 6a).



**Figure 4.** Forest plots of the overall mean effect size for all studies examining the outcomes of (a) TNF- $\alpha$ , (b) interleukin (IL)-6, (c) IL-8, (d) IL-10, (e) interferon (IFN)- $\gamma$ , (f) salivary immunoglobulin A (IgA), (g) IL-1 $\beta$ , (h) IL-2, (i) IL-4, and (j) C-reactive protein (CRP).

## 3.7. Outcome of IL-6

The effect size of five RCTs for the outcome of IL-6 was 0.19 (95% Cl: -0.25, 0.63, p = 0.39; heterogeneity: chi-square = 4.00, df = 4, p = 0.41,  $I^2 = 0\%$ ). The probiotic group exhibited no significant change in the IL-6 level compared with the control group (Figure 4b). In the subgroup analysis, for a shorter intervention period, the probiotic group exhibited no significant change in the IL-6 level compared with the control group, with an effect size of -0.11 (95% Cl: -4.56, 4.34, p = 0.96; heterogeneity: chi-square = 0.97, df = 2, p = 0.62,  $I^2 = 0\%$ ). For a longer intervention period, the probiotic group exhibited no significant change in the IL-6 level compared with the control group (95% Cl: -0.25, 0.64, p = 0.38; heterogeneity: chi-square = 3.01, df = 1, p = 0.08,  $I^2 = 67\%$ ; Figure 5b).

In the subgroup analyses of the timing of postintervention blood sampling, the subgroup whose blood sample collection was delayed to at least the next day of exercise demonstrated no significant change in the IL-6 level compared with the control group, with an effect size of -0.77 (95% Cl: -1.91, 0.37, p = 0.18; heterogeneity: chi-square = 0.19, df = 1, p = 0.66, I<sup>2</sup> = 0%). The subgroup whose blood samples were collected immediately after exercise revealed no significant change in the IL-6 level compared with the control group, with an effect size of 0.36 (95% Cl: -0.11, 0.84, p = 0.14; heterogeneity: chi-square = 0.55, df = 2, p = 0.76, I<sup>2</sup> = 0%; Figure 6b).

# 3.8. Outcome of IL-8

The effect size of four RCTs for the outcome of IL-8 was -0.57 (95% Cl: -1.33, 0.19, p = 0.14; heterogeneity: chi-square = 12.68, df = 3, p = 0.01, I<sup>2</sup> = 76%). The probiotic group exhibited no significant change in the IL-8 level compared with the control group (Figure 4c).


In the subgroup analysis of the intervention period, for a shorter intervention period, the probiotic group exhibited no significant change in the IL-8 level compared with the control group, with an effect size of -1.23 (95% Cl: -2.48, 0.03, p = 0.06; heterogeneity: chi-square = 11.05, df = 2, p = 0.004,  $I^2 = 82\%$ ). For a longer intervention period, the probiotic group demonstrated no significant change in the IL-8 level compared with the control group, with an effect size of -0.20 (95% Cl: -1.15, 0.75, p = 0.68; Figure 5c).

In the subgroup analysis based on the timing of postintervention blood sampling, the subgroup whose blood sample collection was delayed to at least the next day of exercise exhibited no significant change compared with the control group, with an effect size of -0.17 (95% Cl: -1.11, 0.77, p = 0.72; heterogeneity: chi-square =  $0.16, df = 1, p = 0.69, I^2 = 0\%$ ). The subgroup whose blood samples were collected immediately after exercise exhibited a significant negative change in the IL-8 level compared with the control group, with an effect size of -1.31 (95% Cl: -2.59, -0.04, p = 0.05; heterogeneity: chi-square =  $10.56, df = 1, p = 0.001, I^2 = 91\%$ ; Figure 6c).

## 3.9. Outcome of IL-10

The effect size of five RCTs for the outcome of IL-10 was -0.13 (95% Cl: -0.19, -0.06; p = 0.0001, heterogeneity: chi-square = 5.01, df = 4, p = 0.29, I<sup>2</sup> = 20%). The probiotic group exhibited a significant negative change in the IL-10 level compared with the control group (Figure 4d).

In the subgroup analysis based on the intervention period, for a shorter intervention period, the probiotic group exhibited a significant negative change in the IL-10 level compared with the control group, with an effect size of -0.13 (95% Cl: -0.19, -0.06, p = 0.0002; heterogeneity: chi-square = 4.67, df = 3, p = 0.20, I<sup>2</sup> = 36%). For a longer intervention period, the probiotic group exhibited no significant change in the IL-10 level compared with the control group, with an effect size of -0.33 (95% Cl: -1.01, 0.35, p = 0.34; Figure 5d).



**Figure 5.** Forest plots of the mean effect size for the subgroups with a shorter and longer intervention period for (a) TNF $-\alpha$ , (b) IL-6, (c) IL-8, and (d) IL-10.

111 - 3       Dependmental       Control       Mean Difference       Mean Difference       Mean Difference         - Start Vision Lines       0.00       1.00	) TNF-a	<b>F</b> .		<b>.</b>			B	· · · · · · · · · · · · · · · · · · ·
1.5.1.11 We advanced to at least the need day of exercise						Weight	Mean Difference IV, Fixed, 95% Cl	Mean Difference IV, Fixed, 95% Cl
$ \begin{array}{llllllllllllllllllllllllllllllllllll$								
Simular Line Scare (a) 2020         1.54         0.87         24         0.05         4.05         (5.08)         0.05         0.06         0.07         0.07         0.06         0.06         0.06         0.06         0.06         0.06         0.06         0.06         0.06         0.06         0.06         0.06         0.06         0.06         0.07         0.06         <								
Subtract (25% C) 52 (54 (4.0, 0.13) Test for versile lists $Z = 3.29 + 0.000$ () 14.10.7 12.135 1.25 12 19.5% 0.05 (0.88, 0.89) Test for versile lists $Z = 3.29 + 0.000$ () 15.2 2.10 ( $M = 0.000$ () Test for versile lists $Z = 3.29 + 0.000$ () Test for versile lists $Z = 3.29 + 0.000$ () Test for versile lists $Z = 4.27 + 0.000$ () Test for versile lists $Z = 4.27 + 0.000$ () Test for versile lists $Z = 4.27 + 0.000$ () Test for versile lists $Z = 4.27 + 0.000$ () Test for versile lists $Z = 4.27 + 0.000$ () Test for versile lists $Z = 4.27 + 0.000$ () Test for versile lists $Z = 4.27 + 0.000$ () Test for versile lists $Z = 4.27 + 0.000$ () Test for versile lists $Z = 4.27 + 0.000$ () Test for versile lists $Z = 4.27 + 0.000$ () Test for versile lists $Z = 4.27 + 0.000$ () Test for versile lists $Z = 4.27 + 0.000$ () Test for versile lists $Z = 4.27 + 0.000$ () Test for versile lists $Z = 4.27 + 0.000$ () Test for versile lists $Z = 4.27 + 0.000$ () Test for versile lists $Z = 4.27 + 0.000$ () Test for versile lists $Z = 4.27 + 0.000$ () Test for versile lists $Z = 4.37 + 0.000$ () Test for versile lists $Z = 4.37 + 0.000$ () Test for versile lists $Z = 4.37 + 0.000$ () Test for versile lists $Z = 4.37 + 0.000$ () Test for versile lists $Z = 4.37 + 0.000$ () Test for versile lists $Z = 4.37 + 0.000$ () Test for versile lists $Z = 4.37 + 0.000 ()$ Test for versile lists $Z = 4.37 + 0.000 ()$ Test for versile lists $Z = 4.37 + 0.000 ()$ Test for versile lists $Z = 4.37 + 0.000 ()$ Test for versile lists $Z = 4.30 + 0.000 ()$ Test for versile lists $Z = 4.30 + 0.000 ()$ Test for versile lists $Z = 4.30 + 0.000 ()$ Test for versile lists $Z = 4.30 + 0.000 ()$ Test for versile lists $Z = 4.30 + 0.000 ()$ Test for versile lists $Z = 4.000 + 0.000 ()$ Test for versile lists $Z = 4.000 + 0.000 ()$ Test for versile lists $Z = 4.000 + 0.000 ()$ Test for versile lists $Z = 4.000 + 0.000 ()$ Test for versile lists $Z = 4.000 + 0.000 ()$ Test for versile lists $Z = 2.000 ()$ Tes								<b>_</b>
Test for worst direct 2 = 3.29 = 0.0001)         14.2 TH 4 interactive versions         15.2 TH 4 interactive versions         16.2 TH 4 interactive versions         16.2 TH 4 interactive versions         17.4 TH 5 interactive versions         17.4 TH 5 interactive versions         18.4 C 5 interactive versions         18		1.04 0.07						◆
Balachina 2020 1. 1.4 10.7 12 135 1.25 12 195 0.05 ( $ha36, 0.89$ ) Transes Silve 2011 1. 0.65 7. 1.56 0.45 0.42 0.45 0.43 0.43 Wet 2011 1. 22 0.1 7 168 2.06 60 2.55 0.46 ( $ha36, 0.89$ ) Wet 2011 1. 22 0.1 7 168 2.06 60 2.55 0.45 ( $ha36, 0.89$ ) Wet 2011 1. 22 0.1 7 168 2.06 60 2.55 0.45 ( $ha36, 0.89$ ) Hencogenetic $L^2 = 4.71 (P = 0.000)$ 118 123 100.0% 0.29 ( $ha42, 0.46$ ) Hencogenetic $L^2 = 4.71 (P = 0.000)$ 118 123 100.0% 0.29 ( $ha42, 0.46$ ) Hencogenetic $L^2 = 4.71 (P = 0.000)$ 118 123 100.0% 0.29 ( $ha42, 0.46$ ) Hencogenetic $L^2 = 4.71 (P = 0.000)$ 118 123 100.0% 0.29 ( $ha42, 0.46$ ) Hencogenetic $L^2 = 4.71 (P = 0.000)$ 118 123 100.0% 0.29 ( $ha42, 0.46$ ) Hencogenetic $L^2 = 4.71 (P = 0.000)$ 118 123 100.0% 0.29 ( $ha42, 0.46$ ) Hencogenetic $L^2 = 4.07 (P = 0.000)$ 118 123 100.0% 0.29 ( $ha42, 0.46$ ) Hencogenetic $L^2 = 4.07 (P = 0.000)$ 120 112 120 122 9 0.25 0.31 120 124 120 120 120 120 120 120 120 120 120 120				1%				
Transcelline 2021 1:1 0.65 7 1.98 0.4 7 5 15 - 0.88 [ $1.4$ , 0.28] Wet 2011 1:2 201 47 168 20 9 0 2.5% - 0.48 [ $1.5$ , 0.28] Subtated (5% C) C = 0.12, $P = 0.5$ , $P = 2.5$ , $P$		-		25 1 24	. 12	1.0%	0.051.0.99.0.091	
West 2011         1.22         2.01         47         1.82         2.09         60         2.5%         -0.45         1.2.8         0.43           Heterogenety, Chill = 2.7, at $2 = 0 = 0.3$ , $F = 20\%$ Factor censil diffect Z = 7.17         1.23         100.0%         -2.25         4.24         0.45           Heterogenety, Chill = 1.84, at $a \leq 2.00$ , $F = 2.0\%$ Test or overall diffect Z = 7.17         0.000         -2.25         4.24         0.45           Start or overall diffect Z = 7.17         For overall diffect Z = 7.17         0.000         -2.25         -2.44<								(
Heisogeneity: Ch <sup>2</sup> = 2.9 ( $1^{2} = 2.0 = 2.0$ ). Test for overall effect: $2 = 2.7 (1^{2} = 0.000)$ . Test for overall effect: $2 = 4.7 (P = 0.000)$ . Test for overall effect: $2 = 4.7 (P = 0.000)$ . Test for overall effect: $2 = 4.7 (P = 0.000)$ . Test for overall effect: $2 = 4.7 (P = 0.000)$ . Test for overall effect: $2 = 4.7 (P = 0.000)$ . Test for overall effect: $2 = 4.7 (P = 0.000)$ . Test for overall effect: $2 = 4.7 (P = 0.000)$ . Test for overall effect: $2 = 4.7 (P = 0.000)$ . Test for overall effect: $2 = 4.3 (P = 0.10)$ . Test for overall effect: $2 = 4.3 (P = 0.10)$ . Test for overall effect: $2 = 4.3 (P = 0.10)$ . Test for overall effect: $2 = 4.3 (P = 0.10)$ . Test for overall effect: $2 = 4.3 (P = 0.10)$ . Test for overall effect: $2 = 1.3 (P = 0.10)$ . Test for overall effect: $2 = 1.3 (P = 0.10)$ . Test for overall effect: $2 = 1.3 (P = 0.10)$ . Test for overall effect: $2 = 1.3 (P = 0.10)$ . Test for overall effect: $2 = 1.3 (P = 0.10)$ . Test for overall effect: $2 = 1.4 (P = 0.00)$ . Test for overall effect: $2 = 1.4 (P = 0.00)$ . Test for overall effect: $2 = 0.3 (P = 0.0)$ . Test for overal	West 2011		47 1		3 50	2.5%	-0.46 [-1.28, 0.36]	
$ \begin{aligned} & \text{Heterogenety: } Ch^{\mu} = 16.4, df = 0 = 0.000; r = 70\%, \\ & \text{Test for varial effect: Z = 4.7 P < 0.0000; 1 \\ & \text{Test for varial effect: Z = 4.7 P < 0.0000; 1 \\ & \text{Test for varial effect: Z = 4.7 P < 0.0000; 1 \\ & \text{Test for varial effect: Z = 4.7 P < 0.0000; 1 \\ & \text{Test for varial effect: Z = 4.7 P < 0.0000; 1 \\ & \text{Test for varial effect: Z = 4.7 P < 0.0000; 1 \\ & \text{Test for varial effect: Z = 4.7 P < 0.0000; 1 \\ & \text{Test for varial effect: Z = 1.3 P = 0.18, P = 4.0 %, \\ & \text{Mean Difference} \\ & Favours (experimental P < 0.000; P = 0.000; $	Heterogeneity: Chi <sup>2</sup> = 2		5); F= 28%		69	9.5%	-0.57 [-0.99, -0.16]	-
Test for overall effect Z = 4.3 (f = 0.0001) Test for subjourned Effect Z = 1.3 (f = (f = 0.15), F = 48.0% IL-5 Study of Stington Mean. D5 Total. Mean. D5 Total. Weint M. Kitxed. 95% CL At.1L.6 delayed to at least the next day of exercise Pup 2019 0.95 7.34 (f = 1.15, 0.32 (f = 0.16), F = 0.8, Test for overall effect Z = 1.3 (f = (f = 0.66), F = 0.8, Test for overall effect Z = 1.3 (f = 0.16), F = 0.8, Test for overall effect Z = 1.3 (f = 0.16), F = 0.8, Test for overall effect Z = 1.3 (f = 0.16), F = 0.8, Test for overall effect Z = 1.3 (f = 0.16), F = 0.8, Test for overall effect Z = 1.3 (f = 0.16), F = 0.8, Test for overall effect Z = 1.3 (f = 0.16), F = 0.8, Test for overall effect Z = 1.3 (f = 0.16), F = 0.8, Test for overall effect Z = 1.3 (f = 0.16), F = 0.8, Test for overall effect Z = 1.3 (f = 0.16), F = 0.8, Test for overall effect Z = 1.3 (f = 0.16), F = 0.05, H = 0.	Total (95% CI)		118		123	100.0%	-0.29 [-0.42, -0.16]	•
Test for subgroup differences: Ch <sup>2</sup> = 1.9; d = 1 ( <i>p</i> = 0.10; <i>p</i> = 4.00% Mean Difference Study of Subgroup Mean SD. Total Mean SD. Total Weight M. (Excl. 55% Cl. 4.1.1.6. 46 used to at least the next day of exercise Puph 2019 9.05 7.34 11 12.76 12.32 9 0.2% - 2.81 (+1.9.5, 6.33) Vest 201 0.84 2.47 47 1.59 3.26 50 14.7% - 0.74 (+1.80, 0.41) Heikerogeneity. Ch <sup>2</sup> = 0.16, 0 - 10.9; <i>p</i> = 0.50; <i>p</i> = 0.50; Test for overall effect Z = 1.3 ( <i>p</i> = 0.50; <i>p</i> = 0.50; Exitod at (55% Cl) 1.32 6 7.53 7 10.72 6.56 16 94.5%, 0.35 (+0.17, 0.44) Heikerogeneity. Ch <sup>2</sup> = 0.40, 0 - 88 9 3 100.0% 0.19 (-0.25, 0.51) Test for overall effect Z = 0.16, 0 - 5 10, 0 - 5 10 Test for overall effect Z = 0.16, 0 - 5 10, 0 - 5 10 Test for overall effect Z = 0.16, 0 - 5 10, 0 - 5 10 Test for overall effect Z = 0.16, 0 - 5 10, 0 - 5 10 Test for overall effect Z = 0.16, 0 - 6 88 9 3 100.0% 0.19 (-0.25, 0.51) Heikerogeneity. Ch <sup>2</sup> = 4.00, 0 - 6 89 3 100.0% 0.19 (-0.25, 0.51) Heikerogeneity. Ch <sup>2</sup> = 4.00, 0 - 6 89 3 100.0% 0.19 (-0.25, 0.51) Heikerogeneity. Ch <sup>2</sup> = 4.00, 0 - 6 89 3 100.0% 0.19 (-0.25, 0.51) Heikerogeneity. Ch <sup>2</sup> = 4.00, 0 - 6 30, 0 - 7 3 30 30 0 - 5 5 10 Test for overall effect Z = 0.85 (- 10.07), <i>p</i> = 80.3% L-3 L-3 Experimental Control Mean Difference Study or Subgroup differences: Ch <sup>2</sup> = 3.26 4.60 2, 71 4.50 2, 71 4.50 2, 72 4.50 2				1%				
Study or Subgroup         Mean         SD. Total         Mean         SD. Total         Weight         M. Fixed, 95% CI           Pup 2019         9.95         7.34         11 1276         12.32         9         0.2%         -28 [11 13.6, 63.3]           Viet 2011         0.84 2.47         7         15.8         3.26         50         1.47%         -0.74 [1.89, 0.31]           Studytal (65% C)         1.83         7.83         12         1.58         3.26         50         1.47%         -0.74 [1.89, 0.37]           Heterogeneity, Chi = 0.163         1.33         7.53         12         1.64         6.11         -0.26         6.0.1%         -3.84         0.36 [0.11, 0.37]           Heterogeneity, Chi = 0.55, (f = 0.75), F = 0.%         50         1.63         8.3         0.36 [0.21, 10.04]         -0.55         1.0           Fast for overall effect Z = 0.85         0.138         7.53         2.1 (1.64, 6.21)         0.55         1.0         -10         -5         0         5         1.0           Fast for overall effect Z = 0.85         0.20         7.1         8.50         0.21 (1.0.64, 6.25)         0.50         1.0         Fasours (Eoperimetal Evolution)           Fast for overall effect Z = 0.80         Eoperimetal         Control<	Test for subgroup diffe			0.16), P	= 49.0%	5		Favours (experimental) Favours (control)
1.4.1.6. delayed to all least the next day of exercise         Puph 2019       9.95       0.2%       -281 [+11.95, 6.33]         Visit 2011       0.94 2.47       47 1.58 3.26       50       1.4.7%       -0.74 [+1.95, 6.33]         Visit 2011       0.94 2.4.7       47 1.58 3.26       50       1.4.9%       0.2%       -281 [+1.95, 6.33]         Visit 2011       0.84 2.4.7       7 1.58 3.26       50       1.4.9%       0.27       1.4.9%       0.27       1.4.28       0.27       1.4.2       0.56       1.4.2       0.56       1.4.2       0.56       0.1.1       0.4.1       0.2.6.2       1.4.2       0.56       1.0.6.5       1.0.6.5       1.0.6.5       1.0.6.5       1.0.6.5       1.0.6.5       1.0.6.5       1.0.6.5       1.0.6.5       1.0.6.5       1.0.6.5       1.0.6.5       1.0.6.5       1.0.6.5       1.0.6.5		Experimental	с					
Puph 2019 9:05 7.3 4 11 1276 12.32 9 0.2% -28 [119.56, 53] Vest 2011 0.84 2.47 47 158 3.26 50 14.7% -0.74 [1.80, 0.41] Subtrate [45% CD] 58 2.43 7 10.7 2.83 60 1.4% -0.77 [1.91, 0.37] Heterogeneity. Chill = 0.16, 0 = 0.65, 0 = 0.55, 0 = 0.55 1.4.2 L.6 immediately after exercise Batatinha 2020 13.38 7.53 12 11.94 6.21 12 0.6% 1.52 [4.00, 7.04] Guero-Catero 2022 6.23 4.3 7 10.72 9.8 6 0.1% -3.89 (0.94 (0.9					Total V	Veight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
Vest 2011       0.24       2.47       1.58       3.26       50       1.47%       -0.77 [-1.33, 0, 0.37]         Heberogenely, Ch7= 0.19, df=1 ( $P = 0.60$ ); P= 0%       Test for overall effect Z = 1.33 ( $P = 0.10$ )       59       14.9%       0.77 [-1.91, 0.37]         1.4.21.6.5 immediately after exercise       Estatime added of the exercise       0.1%       -3.80 [-1.60, 0.7.04]         0.uero-Calero 2021       5.02       1.3       7       10.72       8.8       0.1%       -3.80 [-1.60, 0.7.04]         0.uero-Calero 2021       0.11       0.64       1       0.25       0.5       1.6       9.4.3%       0.35 [-0.12, 0.83]         1.42t.6.5 immediately after exercise       0.1%       -3.80 [-1.60, 0.7.04]       0.8       9.3       100.0%       0.19 [-0.25, 0.6.3]         1.6       7.61       7.6       0.5       0.5       1.0       Favours [experimental Courtol       Mean Difference         Stuto at (95% Ci)       7.2       5.4       7.1       9.8       0.2.7 [-1.31, 0.7]         1.8       Experimental       Courtol       Mean Difference       Mean Difference         Stuto at (95% Ci)       7.2       5.4       7.1       1.5       7.1       1.6       7.1       1.6       7.1       1.6       7.1       1.			-		0	0.204	2 91 L11 05 6 221	
Subtotal (95% C) 58 59 14.9% -0.77 [-1.91, 0.37] Heterogeneity. Ch <sup>2</sup> = 0.169, P = 0.660, P = 0.80 <b>1.4.21.6</b> immediately after exercise Batatinha 2020 13.36 7.53 12 11.84 6.21 12 0.8% 1.52 [-4.00, 7.04] Cuero-Calero 2022 592 14.3 7 10.72 8.8 6 0.1% -3.30 [-1.58, 9.38] Schreiber 2021 0.11 0.44 11 -0.25 0.8 16 84.3% 0.35 [-1.0, 0.44] Heterogeneity. Ch <sup>2</sup> = 0.06 (P = 0.70), P = 0.8 Statuto at 205% C) 30 73 4 85.1% 0.36 [-0.11, 0.84] Heterogeneity. Ch <sup>2</sup> = 0.06 (P = 0.4), P = 0.8 Subtotal (95% C) 50 Total Mean 5D Total Mean Difference Study or Stingroup Mieron esc. Che 7 0.97 (P = 0.005), P = 0.8 Subtotal (95% C) 77 7 77 100.0% -0.57 [-1.33, 0.19] Heterogeneity. Ch <sup>2</sup> = 1.48 (P = 0.005), P = 0.8 Subtotal (95% C) 77 7 77 100.0% -0.57 [-1.33, 0.19] Heterogeneity. Ch <sup>2</sup> = 1.28, df = 1 (P = 0.05), P = 0.8 Subtotal (95% C) 77 7 77 100.0% -0.57 [-1.33, 0.19] Heterogeneity. Ch <sup>2</sup> = 1.28, df = 0.005), P = 0.8 Subtotal (95% C) 77 7 77 100.0% -0.57 [-1.33, 0.19] Heterogeneity. Ch <sup>2</sup> = 1.28, df = 1 (P = 0.05), P = 0.8 Subtotal (95% C) 77 7 7 100.0% -0.57 [-1.33, 0.19] Heterogeneity. Ch <sup>2</sup> = 1.28, df = 0.005), P = 0.8 Subtotal (95% C) 77 7 7 100.0% -0.57 [-1.33, 0.19] Heterogeneity. Ch <sup>2</sup> = 1.28, df = 0.005), P = 0.8 Subtotal (95% C) 77 7 7 100.0% -0.57 [-1.33, 0.19] Heterogeneity. Ch <sup>2</sup> = 1.28, df = 0 = 0.005), P = 7.8 Subtotal (95% C) 77 7 7 100.0% -0.57 [-1.33, 0.19] Heterogeneity. Ch <sup>2</sup> = 1.28, df = 0 = 0.005), P = 7.8 Subtotal (95% C) 77 7 0 10.6 8 7.9% -0.12 [-0.19, -0.05] Subtotal (95% C) 77 7 0 0.06 8 7.9% -0.12 [-0.19, -0.05] Heterogeneity. Ch <sup>2</sup> = 1.28, df = 0 = 0.005). Total (95% C) 77 7 0 1.14 12 0.06 8 57 1.24 4.51, 0.05] Heterogeneity. Ch <sup>2</sup> = 1.28, df = 0 = 0.005). Total (95% C) 77 7 0 1.14 50.277 9 0.11% -0.68 [-3.43, 2.06] Heterogeneity. Ch <sup>2</sup> = 2.04 (P = 0.005). Total (95% C) 77 7 0 0.1% -0.58 [-3.43, 2.06] Heterogeneity. Ch <sup>2</sup> = 2.04 (P = 0.007). Test for overall effect Z = 7.24 (P = 0.007). Test for overall effect Z = 7.24 (P = 0.007). Test for overall effect Z = 7.24	-							
Test for overall effect $Z = 1.33$ ( $P = 0.10$ ) <b>1.4.2</b> L.6 immediate/after exercise Batatinha 2020 13.36 7.51 12 11.84 6.21 12 0.6% 1.52 (4.00, 7.04) Cuero-Calero 2022 6.92 14.3 7 10.72 8.8 6 0.1% -3.80 (15.6).8, 9.8 (3.8) Starbieter 2022 0.01 0.04 11 0.25 0.05 16 84.3% 0.35 (1.0, 0.84) Heterogeneity (Ch <sup>2</sup> = 4.0, 0 - 8 0.97 (P = 0.75), P = 0% Test for overall effect $Z = 1.08$ ( $P = 0.14$ ) Total (65% Ch) 5.0 Total ( $P = 0.07$ ), P = 69.3% L-8 Experimental Control Man Difference Study of Stingroup Miterones: Chi = 3.25, df = 1 (P = 0.07), P = 69.3% L-8 Experimental Control Man Difference Study of Stingroup Miterones: Chi = 3.57 (at 1.16, at 1.15, 0.81, 3.11) Cuero-Calero 2022 1.91 1.04 11 9.98 4.85 9 1.2% 1.22 (5.72, 8.15) Yietrogeneity: Chi = 0.16, df = 1 (P = 0.65), P = 0% Test for overall effect $Z = 0.36$ ( $P = 0.05$ ), P = 0% Test for overall effect $Z = 0.36$ ( $P = 0.05$ ), P = 0% Test for overall effect $Z = 0.36$ ( $P = 0.05$ ), P = 0% Test for overall effect $Z = 0.36$ ( $P = 0.05$ ), P = 0% Test for overall effect $Z = 0.36$ ( $P = 0.05$ ), P = 0% Test for overall effect $Z = 0.36$ ( $P = 0.05$ ), P = 0% Test for overall effect $Z = 2.00$ ( $P = 0.05$ ). Total (65% Ch) 77 77 77 100.0% -0.57 [-1.33, 0.19] Heterogeneity: Chi = 1.28, df = 1 (P = 0.015), P = 15% Test for overall effect $Z = 2.00$ ( $P = 0.005$ ). Total (65% Ch) 77 77 70 0.0% -0.57 [-1.33, 0.19] Heterogeneity: Chi = 1.28, df = 1 (P = 0.015), P = 15% Test for overall effect $Z = 2.00$ ( $P = 0.005$ ). Total (65% Ch) 77 77 0.0.0% -0.57 [-1.33, 0.19] Heterogeneity: Chi = 1.28, df = 1 (P = 0.015), P = 15% Test for overall effect $Z = 1.48$ ( $P = 0.005$ ). Total (65% Ch) 77 77 0.0.6 8 9.7.9% -0.12 [-0.19, -0.05] Heterogeneity: Chi = 1.28, df = 1 (P = 0.015), P = 49.0% L-10 Experimental Control A 9.7.9% -0.12 [-0.19, -0.05] Heterogeneity: Chi = 2.00, df = 3 (P = 0.005). Total (65% Ch) 77 77 7 0.0.7% -0.51 [-0.33, 0.05] Heterogeneity: Chi = 2.28, df = 0.005, P = 0.0% Heterogeneity: Chi = 2.28, df = 0.005, P = 0.0% Heterogenei	Subtotal (95% CI)		58					◆
1.4.2 IL-6 immediately after exercise         Batainha 2020       13.38       7.53       1.21       0.6%       1.52 [4.00, 7.04]         Outro-Celero 202       6.82       1.52 [4.00, 7.04]         Schreiber 2021       0.11       0.64       1.52 [4.00, 7.04]         Feed to verial effect Z = 1.49 (P = 0.14)         Total (95% C)       8       93       10.0%       Colspan="2">Control         Mean Difference         Schwod Subtoal (95% C)       Not subtoal (95% C)       Mean Difference         Mean Differe								
$\begin{array}{c} \text{Quero-Caleiro 2022} & 6.92 & 14.3 & 7 & 10.72 & 9.8 & 6 & 0.1\% & -3.80 (\pm 6.85, 3.8) (\pm 6.95, 3.8) (\pm 6.9$								
Scheeber 2021 0.11 0.64 11 -0.25 0.6 16 64.3% 0.36 [-0.12, 0.84] Heterogeneity: ChP= 0.55, df= 2 ( $P=0.76$ ); P= 0% Test for overall effect Z = 1.49 ( $P=0.76$ ); P= 0% Test for overall effect Z = 1.49 ( $P=0.14$ ) Test for overall effect Z = 0.05 ( $P=0.26$ ); P= 0% Test for overall effect Z = 0.86 ( $P=0.26$ ); D= 0% Test for overall effect Z = 0.86 ( $P=0.26$ ); D= 0% Test for overall effect Z = 0.86 ( $P=0.26$ ); D= 0% Test for overall effect Z = 0.86 ( $P=0.26$ ); D= 0% Test for overall effect Z = 0.86 ( $P=0.26$ ); D= 0% Test for overall effect Z = 0.86 ( $P=0.26$ ); P= 0% Test for overall effect Z = 0.86 ( $P=0.26$ ); P= 0% Test for overall effect Z = 0.86 ( $P=0.26$ ); P= 0% Test for overall effect Z = 0.86 ( $P=0.26$ ); P= 0% Test for overall effect Z = 0.06 ( $P=0.26$ ); P= 0% Test for overall effect Z = 0.06 ( $P=0.26$ ); P= 0% Test for overall effect Z = 0.06 ( $P=0.26$ ); P= 0% Test for overall effect Z = 0.06 ( $P=0.26$ ); P= 0% Test for overall effect Z = 0.06 ( $P=0.26$ ); P= 0% Test for overall effect Z = 0.06 ( $P=0.26$ ); P= 76% Test for overall effect Z = 1.06 ( $P=1.16$ ); P= 1% Test for overall effect Z = 1.06 ( $P=0.16$ ); P= 78% Test for overall effect Z = 1.000; P= 76% Test for overall effect Z = 1.66 ( $P=0.16$ ); P= 78% Test for overall effect Z = 1.66 ( $P=0.16$ ); P= 78% Test for overall effect Z = 1.66 ( $P=0.16$ ); P= 76% Test for overall effect Z = 1.66 ( $P=0.16$ ); P= 76% Test for overall effect Z = 1.66 ( $P=0.16$ ); P= 76% Test for overall effect Z = 1.66 ( $P=0.16$ ); P= 76% Test for overall effect Z = 1.66 ( $P=0.16$ ); P= 76% Test for overall effect Z = 3.50 ( $P=0.000$ ); P= 76% Test for overall effect Z = 3.50 ( $P=0.000$ ); P= 76% Test for overall effect Z = 3.50 ( $P=0.000$ ); P= 76% Test for overall effect Z = 3.50 ( $P=0.000$ ); P= 76% Test for overall effect Z = 3.50 ( $P=0.000$ ); P= 76% Test for overall effect Z = 3.50 ( $P=0.000$ ); P= 76% Test for overall effect Z = 3.50 ( $P=0.000$ ); P= 0% Test for overall effect Z = 3.50 ( $P=0.000$ ); P= 0% Test for overall effect Z = 3.50 ( $P=0.000$ ); P=	Batatinha 2020	13.36 7.53		6.21			1.52 [-4.00, 7.04]	
Subtorial (95% C) 30 mm 30 mm 34 95.1% 0.36 [ $0.11, 0.64$ ] Heterogeneity, Ch <sup>P</sup> = 4.0P (P = 0.14) Total (95% C) 88 93 100.0% 0.19 [ $0.25, 0.63$ ] Heterogeneity, Ch <sup>P</sup> = 4.00, df = 4 (P = 0.14); P = 0% Test for verial effect Z = 1.49 (P = 0.14); P = 0% Test for verial effect Z = 1.49 (P = 0.14); P = 0% Test for verial effect Z = 0.56 (P = 0.39) Test for verial effect Z = 0.56 (P = 0.39) Test for verial effect Z = 0.56 (P = 0.39) Test for verial effect Z = 0.56 (P = 0.39) Test for verial effect Z = 0.56 (P = 0.39) Test for verial effect Z = 0.56 (P = 0.39) Test for verial effect Z = 0.608; P = 0.72 18.21L 3 delayed to at least the next day of exercise Pugh 2019 11.21 10.46 11 9.89 4.86 9 1.2% 1.23 ( $5.72, 8.18$ ) West 2011 0.77 2.55 47 0.97 2.19 50 83.8% -0.20 ( $1.15, 0.78$ ) Subtorial (95% C) 2.77 1.48 12 5.95 3.13 12 15.0% 1.15 ( $0.81, 3.11$ ) Ouero-Calero 202 1.9 1.23 7 5.04 1.78 6 5 20 1% -0.31 ( $1.48, 8.2, 1.48$ ) Heterogeneity, Ch <sup>P</sup> = 0.16, df = 1 (P = 0.060); P = 0% Test for verial effect Z = 0.26 (P = 0.72) 18.21L 3 immediately after exercise Batatinha 2020 7.1 1.48 (P = 0.01); P = 91% Test for verial effect Z = 1.28, df = 2 (P = 0.005); P = 75% Test for verial effect Z = 1.28, df = 2 (P = 0.005); P = 75% Test for verial effect Z = 1.28, df = 2 (P = 0.005); P = 75% Test for verial effect Z = 1.36, df = 1 (P = 0.16), P = 49.0% L1-10 Experimental Expours (Experimental Expours (control) Heterogeneity; Not applicable Test for verial effect Z = 3.50 (P = 0.005); P = 75% Test for verial effect Z = 3.50 (P = 0.005); P = 75% Test for verial effect Z = 3.50 (P = 0.005); P = 77 6 9.79% -0.12 [0.19, -0.05] Heterogeneity; Not applicable Test for verial effect Z = 3.50 (P = 0.005); P = 77 7 6 9.79% -0.12 [0.19, -0.05] Heterogeneity; Not applicable Test for verial effect Z = 2.20, df = 3 (P = 0.56); P = 0.07 Test for verial effect Z = 2.30; P = 0.05; P = 0.05 Test for verial effect Z = 2.30; P = 0.05; P = 0.05 Test for verial effect Z = 2.30; P = 0.05; P = 0.05 Test for verial effe								
Heierogeneity: Ch <sup>2</sup> = 0.55, df = 2 ( $P = 0.70$ ); $P = 0\%$ Test for overall effect Z = 1.49 ( $P = 0.14$ ) Total (95% CI) 88 93 100.0% 0.19 [.0.25, 0.63] Heierogeneity: Ch <sup>2</sup> = 2.08 ( $P = 0.39$ ) Test for overall effect Z = 0.86 ( $P = 0.39$ ) Test for overall effect Z = 0.86 ( $P = 0.39$ ) Test for overall effect Z = 0.86 ( $P = 0.39$ ) Test for overall effect Z = 0.86 ( $P = 0.39$ ) Test for overall effect Z = 0.86 ( $P = 0.39$ ) Test for overall effect Z = 0.86 ( $P = 0.39$ ) Test for overall effect Z = 0.86 ( $P = 0.39$ ) Test for overall effect Z = 0.86 ( $P = 0.39$ ) Test for overall effect Z = 0.86 ( $P = 0.39$ ) Total (95% CI) 1.121 10.46 11 9.98 4.86 9 1.2% 1.23 [-5.7, 0.16] Subtotal (95% CI) 7.255 47 0.07 2.19 50 63.28% -0.021 [-1.60.75] Subtotal (95% CI) 7.255 47 0.05 ( $P = 0.59$ ); $P = 0\%$ Test for overall effect Z = 0.36 ( $P = 0.72$ ) 18.2 L.8 immediately after exercise Eatalinha 200 7.1 1.46 12 5.95 3.13 12 150% 1.15 [-0.81, 3.11] Outroic-Calaro 2022 1.9 1.23 7 5.04 1.78 6 201% -0.13 [-2.59, 0.03] Heiterogeneity: Ch <sup>2</sup> = 1.0.50, df = 1 ( $P = 0.001$ ); $P = 91\%$ Test for overall effect Z = 0.00 ( $P = 0.05$ ); $P = 75\%$ Test for overall effect Z = 1.48 ( $P = 0.16$ ); $P = 19\%$ Test for overall effect Z = 1.48 ( $P = 0.16$ ); $P = 75\%$ Test for overall effect Z = 1.48 ( $P = 0.16$ ); $P = 19\%$ Test for overall effect Z = 1.48 ( $P = 0.16$ ); $P = 19\%$ Test for overall effect Z = 3.00 ( $P = 0.05$ ); $P = 75\%$ Test for overall effect Z = 3.00 ( $P = 0.05$ ); $P = 75\%$ Test for overall effect Z = 3.00 ( $P = 0.05$ ); $P = 75\%$ Test for overall effect Z = 3.50 ( $P = 0.005$ ); $P = 75\%$ Test for overall effect Z = 3.50 ( $P = 0.005$ ); $P = 75\%$ Test for overall effect Z = 3.50 ( $P = 0.005$ ); $P = 75\%$ Test for overall effect Z = 2.00; $P = 0.005$ ; $P = 76\%$ , $-0.12$ [-0.19, -0.05] Test for overall effect Z = 2.00; $P = 0.005$ ; $P = 76\%$ , $-0.12$ [-0.19, -0.05] Test for overall effect Z = 2.00; $P = 0.005$ ; $P = 76\%$ , $-0.22$ [-0.05] Test for overall effect Z = 2.00; $P = 0.005$ ; $P = 0.005$ ; $P = 0.005$ ; $P$				0.6				<b>T</b>
Total (95% C) 88 93 100.0% 0.19 [-0.25, 0.63] Heterogeneity: Chi <sup>P</sup> = 4.00, df - 4 ( $P = 0.41$ ); $P = 0$ % Test for voerall effect: Z = 0.86 ( $P = 0.39$ ) Test for voerall effect: Z = 0.85 ( $P = 0.39$ ) Test for voerall effect: Z = 0.85 ( $P = 0.39$ ) Test for voerall effect: Z = 0.85 ( $P = 0.39$ ) Test for voerall effect: Z = 0.85 ( $P = 0.03$ ); $P = 69.3\%$ L-3 Experimental Control Mean Difference Study or Subgroup Mean SD Total Mean Difference Mean Differe	Heterogeneity: Chi <sup>2</sup> =	0.55, df= 2 (P = 0.	76); I²= 0%				2.20 [-0.1 I, 0.04]	Ť
Historgenenity: Chi <sup>2</sup> = 4.00, df = 4 ( $P = 0.41$ ); $P = 0\%$ Test for verail effect $Z = 0.66$ ( $P = 0.39$ ) Test for verail effect $Z = 0.66$ ( $P = 0.39$ ) Test for verail effect $Z = 0.66$ ( $P = 0.39$ ) L-3 L-3 Experimental Control Mean Difference Study of Subgroup differences: Chi <sup>2</sup> = 3.25, df = 1 ( $P = 0.07$ ), $P = 68.3\%$ L-3 L-3 L-3 L-3 Experimental Control Mean Difference Study of Subgroup differences: Chi <sup>2</sup> = 3.25, df = 1 ( $P = 0.07$ ), $P = 68.3\%$ L-3 L-3 L-3 L-3 L-3 L-3 L-3 L-3					93 1	00.0%	0 19 [.0 25 0 63]	•
Test for overall effect $Z = 0.86$ ( $P = 0.39$ ) Test for overall effect $Z = 0.36$ ( $P = 0.39$ ) L-8 Experimental L-8 Experimental L-10 Subtor or subgroup differences: Chi <sup>P</sup> = 3.25, df = 1 ( $P = 0.07$ ), P = 69.3% L-8 Experimental L-10 Subtor of Subgroup Mean SD Total Mean SD Total Weight M. Fixed, 95% CI N. Fixed, 95% CI								<u> </u>
IL-3         Experimental         Control         Mean Difference         Mean Difference           Study or Subgroup         Mean         SD <total< td="">         Total         Mean         SD<total< td="">         Weight         M. Fixed, 95% CI         M. Fixed, 95% CI           11.8.1 LL. 3 delayed to at least the next day of exercise         9         1.2%         1.23 [5.72, 0.18]         Mean         Difference           Pugh 2019         11.21         10.46         11         9.38         4.86         9         1.2%         1.23 [5.72, 0.18]           Subtotal (55% CI)         0.77         2.56         47         0.37         2.13 [5.60%         0.071 [1.11,0.77]           Heterogeneiky: ChP = 0.16, df = 1 (P = 0.69); P = 0%         Test for overall effect Z = 0.36 (ff = 0, 72)         1.14         12         5.95         3.13         12         15.0%         1.15 [-0.81, 3.11]           Quero-Calero 2022         1.9         1.2.3         7         5.04         1.76         6         20.1%         -3.14 [4.48, -1.45]           Subtotal (95% CI)         19         11         5.05         3.50%         -1.31 [2.59, 0.03]         Heterogeneity: ChP = 1.05.6, df = 1 (P = 0.005); P = 7.6%           Test for overall effect Z = 1.48 (P = 0.14)         Total         Mean         SD<total< td="">         M</total<></total<></total<>	Test for overall effect:	Z = 0.86 (P = 0.39)			l² = 69.3	3%		
<b>1.4.1.L.3 delayed to at least the next day of exercise</b> Pugh 2019 11.21 10.46 11 9.98 4.86 9 1.2% 1.23 [-5.72, 8.18] Weist 2011 0.77 2.55 47 0.97 2.19 50 63.8% -0.20 [-1.15, 0.75] Subtotal (95% C) 58 59 65.0% -0.17 [-1.11, 0.77] Heterogeneity: Ch <sup>2</sup> = 0.16, df = 1 ( $P = 0.06$ ); $P = 0\%$ Test for overall effect Z = 0.36 ( $P = 0.72$ ) <b>1.6.2 L.8 immediately after exercise</b> Batalinha 2020 7.1 1.48 12 5.95 3.13 12 15.0% 1.15 [-0.81, 3.11] Quero-Calero 2022 19 1.23 7 5.04 1.78 6 20.1% -3.14 [-4.83, -1.45] Subtotal (95% C) 19 1.23 7 5.04 1.78 6 20.1% -3.14 [-4.83, -1.45] Subtotal (95% C) 19 1.23 7 5.04 1.78 6 20.1% -3.14 [-4.83, -1.45] Test for overall effect Z = 2.00 ( $P = 0.005$ ); $P = 76\%$ Test for overall effect Z = 1.08 ( $d = 3 (P = 0.005$ ); $P = 76\%$ Test for overall effect Z = 1.08 ( $d = 1 (P = 0.16$ ); $P = 49.0\%$ IL-10 Experimental Control Mean Difference Studor Subgroup Mean SD Total ( $P = 0.05$ ) Test for subgroup differences: Ch <sup>2</sup> = 1.96, df = 1 ( $P = 0.16$ ); $P = 49.0\%$ IL-10 Experimental Control Mean Difference Studor Subgroup Mean SD Total Weight IV. Fixed, 95% Cl IV							lean Difference	Mean Difference
Pugh 2019 11.21 10.46 11 9.98 4.86 9 1.2% 1.23 [5.72, 8.18] West 2011 0.77 2.55 47 0.97 2.19 50 63.8% $-0.20 [+1.15, 0.75]$ Heterogeneity: Ch <sup>2</sup> = 0.16, df = 1 ( $P = 0.69$ ); $P = 0\%$ Test for overall effect: Z = 0.36 ( $P = 0.02$ ) 1.8.2 IL-8 immediately after exercise Eatatinha 2020 7.1 1.48 12 5.95 3.13 12 15.0% 1.15 [-0.81, 3.11] Ouero-Calero 2022 1.9 1.23 7 5.04 1.78 6 2.01% $-3.14 [+4.83, -1.45]$ Subtotal (95% Cl) 77 77 77 100.0% $-0.57 [-1.33, 0.19]$ Heterogeneity: Ch <sup>2</sup> = 10.56, df = 1 ( $P = 0.001$ ); $P = 91\%$ Test for overall effect: Z = 1.48 ( $P = 0.14$ ) Test for subgroup differences: Ch <sup>2</sup> = 1.96, df = 1 ( $P = 0.16$ ), $P = 49.0\%$ IL-10 Experimental Exuby or subgroup differences: Ch <sup>2</sup> = 1.96, df = 1 ( $P = 0.16$ ), $P = 49.0\%$ IL-10 Experimental Estudy or subgroup differences: Ch <sup>2</sup> = 1.96, df = 1 ( $P = 0.16$ ), $P = 49.0\%$ IL-10 Experimental Estudy or subgroup differences: Ch <sup>2</sup> = 1.96, df = 1 ( $P = 0.16$ ), $P = 49.0\%$ IL-10 Experimental Estudy or subgroup differences: Ch <sup>2</sup> = 1.96, df = 1 ( $P = 0.16$ ), $P = 49.0\%$ IL-10 Experimental Estudy or subgroup differences: Ch <sup>2</sup> = 1.96, df = 1 ( $P = 0.16$ ), $P = 49.0\%$ IL-10 Experimental Estudy or subgroup differences: Ch <sup>2</sup> = 1.96, df = 1 ( $P = 0.16$ ), $P = 49.0\%$ IL-10 Experimental Estudy or subgroup differences: Ch <sup>2</sup> = 1.96, df = 1 ( $P = 0.16$ ), $P = 49.0\%$ IL-10 Heterogeneity: Ch <sup>2</sup> = 1.26, df = 3 ( $P = 0.005$ ) IL-2.1 L-10 immediately after exercise Batatinha 2020 2.04.03 5 8 12 2.14.14 51.14 12 0.0% 26.69 [+17.06, 70.44] West 2011 0.93 0.71 7 1.02 0.48 7 1.1% -0.69 [+3.13, 2.06] West 2011 0.93 0.77 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7					rotal V	Veight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
West 2011       0.77       2.55       47       0.97       2.19       50       63.8% $-0.20[+1.5], 0.75]$ Subtotal (95% CI)       0.16, df = 1 ( $P = 0.69$ ); $P = 0.69$ , $T = 0.69$ , $P = 0.69$ , $T = 0.69$ , $P = 0.72$ )       18.2 L.8 immediately after exercise         Batatinha 2020       7.1       1.48       12       5.95       3.13       12       15.0%       1.15 [-0.61, 3.11]         Quero-Calero 2022       19       1.23       5.04       1.78       6       20.1%       -3.14 [+4.83, -1.45]         Subtotal (95% CI)       71       1.48       12       5.95       3.13       12       15.0%       1.15 [-0.61, 3.11]         Guero-Calero 2022       19       1.23       7       7.04       7.7       100.0%       -0.57 [-1.33, 0.19]         Heterogeneity, ChP = 10.58, df = 3 (P = 0.005); P = 76%       Test for overall effect Z = 1.86, df = 3 (P = 0.005); P = 76%       Test for overall effect Z = 1.96, df = 1 (P = 0.16), P = 49.0%         IL-10       Experimental       Control       Mean Difference       Mean Difference       Mean Difference         Stubtotal (95% CI)       7       0.05       0.07       6       97.9%       -0.12 [-0.19, -0.05]       Heat 95% CI         I-2.1 L-10 delayed to at least the next day of exercrise       Batalinha 2020       20.	-		-			4.00	4 22 ( 5 72 0 40)	
Subtotal (95% C) 58 59 65.0% -0.17 [-1.11, 0.77] Heterogeneity: Ch <sup>2</sup> = 0.16, df = 1 ( $P = 0.69$ ); P = 0% Test for overall effect Z = 0.36 ( $P = 0.72$ ) <b>1.8.2 IL.8 immediately after exercise</b> Batatinha 2020 7.1 1.48 12 5.95 3.13 12 15.0% 1.15 [-0.81, 3.11] Cuero-Calero 2022 1.9 1.23 7 5.04 1.78 6 20.1% -3.14 [+4.83, -1.46] Subtotal (95% CI) 19 18 35.0% -1.31 [-2.59, -0.03] Heterogeneity: Ch <sup>2</sup> = 1.056, df = 1 ( $P = 0.001$ ); P = 91% Test for overall effect Z = 2.00 ( $P = 0.05$ ); P = 0.05); P = 76% Test for overall effect Z = 1.48 ( $P = 0.16$ ), P = 49.0% Heterogeneity: Ch <sup>2</sup> = 1.268, df = 3 ( $P = 0.005$ ); P = 76% Test for overall effect Z = 1.48 ( $P = 0.16$ ), P = 49.0% IL-10 Experimental Control Subtoral (95% CI) -0.06 0.05 7 0.08 0.07 8 97.9% -0.12 [-0.19, -0.05] Subtotal (95% CI) -0.06 0.05 7 0.08 0.07 8 97.9% -0.12 [-0.19, -0.05] Subtotal (95% CI) -0.06 0.05 7 0.08 0.07 8 97.9% -0.12 [-0.19, -0.05] Heterogeneity: Ch <sup>2</sup> = 2.30 ( $P = 0.0005$ ) <b>1.12.2 IL-10 delayed for exercise</b> Duero 2021 -0.06 0.05 7 0.08 0.07 8 97.9% -0.12 [-0.19, -0.05] Heterogeneity: Ch <sup>2</sup> = 2.00 ( $P = 0.0005$ ) <b>1.12.2 IL-10 immediately after exercise</b> Batatinha 2020 24.083 58 12 214.14 51.14 12 0.0% 26.69 [-17.06, 70.44] Pugh 2019 4.38 3.49 11 5.05 2.77 9 0.1% -0.69 [-3.32, 0.06] Heterogeneity: Ch <sup>2</sup> = 2.08, df = 3 ( $P = 0.0005$ ) <b>1.12.2 IL-10 immediately after exercise</b> Batatinha 2020 2.04.08 7 1.26 1.66 70 1.0% -0.33 [-1.01, 0.35] Subtotal (95% CI) 84 84 100.0% -0.13 [-0.19, -0.06] Heterogeneity: Ch <sup>2</sup> = 2.08, df = 3 ( $P = 0.29$ ); P = 20% Test for overall effect Z = 3.70 ( $P = 0.0001$ ) Test for overall effect Z = 2.74 ( $P = 0.29$ ); P = 20% Test for overall effect Z = 3.79 ( $P = 0.0001$ )	-							
Test for overall effect: $Z = 0.36$ ( $P = 0.72$ ) <b>18.2 IL-8 immediately after exercise</b> Batatinha 2020 7.1 1.48 12 5.95 3.13 12 15.0% 1.15 [-0.81, 3.11] Ouero-Catero 2022 1.9 1.23 7 5.04 1.78 6 20.1% -3.14 [-4.83, -1.45] Subtotal (95% CI) 19 18 35.0% -1.31 [-2.59, -0.03] Heterogeneity: Ch <sup>P</sup> = 10.68, df = 1 ( $P = 0.001$ ); $P = 91\%$ Test for overall effect $Z = 1.48$ ( $P = 0.005$ ); $P = 76\%$ . Test for overall effect $Z = 1.48$ ( $P = 0.005$ ); $P = 76\%$ . Test for overall effect $Z = 1.48$ ( $P = 0.14$ ) Test for subgroup differences: Ch <sup>P</sup> = 1.96, df = 1 ( $P = 0.16$ ), $P = 49.0\%$ LI-10 Experimental Control Mean Difference Study or Subgroup Mean SD Total Mean SD Total Weight N. Fixed, 95% CI 1.12.1 IL-10 delayed to at least the next day of exercise Ouero 2021 -0.06 0.05 7 0.06 0.07 6 97.9% -0.12 [-0.19, -0.05] Subtotal (95% CI) 7 1.02 0.0055 1.12.2 IL-10 immediately after exercise Batatinha 2020 240.83 58 12 214.14 51.14 12 0.0% 26.69 [+17.06, 70.44] Heterogeneity: Not applicable Test for overail effect $Z = 3.50$ ( $P = 0.0005$ ) 1.12.2 IL-10 immediately after exercise Batatinha 2020 240.83 58 12 214.14 51.14 12 0.0% 26.69 [+17.06, 70.44] Heterogeneity: Not applicable Test for overail effect $Z = 3.50$ ( $P = 0.0005$ ) 1.12.2 IL-10 immediately after exercise Batatinha 2020 240.83 58 12 214.14 51.14 12 0.0% 26.69 [+17.06, 70.44] Heterogeneity: Chl <sup>P</sup> = 2.08, df = 3 ( $P = 0.56$ ); $P = 0\%$ Test for overail effect $Z = 2.24$ ( $P = 0.29$ ); $P = 20\%$ Test for overail effect $Z = 3.79$ ( $P = 0.000$ ) Test for overail effect $Z = 3.79$ ( $P = 0.000$ ) Test for overail effect $Z = 3.79$ ( $P = 0.000$ )		0.11 2.00		2.10				
Batatinha 2020 7.1 1.48 12 5.95 3.13 12 15.0% 1.15 [-0.81, 3.11] Guero-Calero 2022 1.9 1.23 7 5.04 1.78 6 20.1% -3.14 [-4.83, -1.45] Subtotal (95% CI) 19 18 35.0% -1.31 [-2.59, -0.03] Heterogeneity: ChP = 10.66, df = 1 (P = 0.001); P = 91% Test for overall effect: $Z = 2.00$ (P = 0.05) Total (95% CI) 77 77 100.0% -0.57 [-1.33, 0.19] Heterogeneity: ChP = 12.68, df = 3 (P = 0.005); P = 76% Test for overall effect: $Z = 1.48$ (P = 0.14) Test for subgroup differences: ChP = 1.96, df = 1 (P = 0.16), P = 49.0% LL-10 Experimental Control Mean Difference Study or Subgroup differences: ChP = 1.96, df = 1 (P = 0.16), P = 49.0% LL-10 delayed to at least the next day of exercise Quero 2021 -0.06 0.05 7 0.08 0.07 6 97.9% -0.12 [-0.19, -0.05] Subtotal (95% CI) 7 0.08 0.07 6 97.9% -0.12 [-0.19, -0.05] Heterogeneity: Not applicable Test for overall effect: $Z = 3.50$ (P = 0.0005) 1.12.2 LL-10 immediately after exercise Batatinha 2020 240.83 58 12 214.14 51.14 12 0.0% 26.69 [-17.06, 70.44] Pugh 2019 4.36 3.49 11 5.05 2.77 9 0.1% -0.69 [-1.32, -0.06] Netstor overall effect: $Z = 3.50$ (P = 0.56); P = 0% Test for overall effect: $Z = 2.24$ (P = 0.29); P = 20% Test for overall effect: $Z = 3.79$ (P = 0.05); P = 0% Test for overall effect: $Z = 3.79$ (P = 0.020) Total (95% CI) 84 84 100.0% -0.13 [-0.19, -0.06] Heterogeneity: ChI <sup>2</sup> = 2.08, df = 3 (P = 0.56); P = 0% Test for overall effect: $Z = 3.79$ (P = 0.0001)							-0.17 [-1.11, 0.77]	-
Quero-Calero 2022       1.9       1.23       7       5.04       1.78       6       20.1%       -3.14 [ $\frac{1}{4}$ 83,-1.45]         Subtotal (95% Cl)       19       18       35.0%       -1.31 [ $-2.59$ , -0.03]         Heterogeneity: Ch <sup>2</sup> = 10.56, df = 3 (P = 0.005); P = 76%       77       100.0%       -0.57 [-1.33, 0.19]         Heterogeneity: Ch <sup>2</sup> = 12.68, df = 3 (P = 0.005); P = 76%       77       100.0%       -0.57 [-1.33, 0.19]         Test for overall effect: Z = 1.48 (P = 0.14)       Test for subgroup differences: Ch <sup>2</sup> = 1.96, df = 1 (P = 0.16), P = 49.0%       Mean Difference       Mean Difference         IL-10       Experimental       Control       Mean SD Total Weight       N. Fixed, 95% Cl       V. Fixed, 95% Cl         1.12.1 L.10 delayed to at least the next day of exercise       Mean Difference       Mean Difference       Mean Difference         Guero 2021       -0.06 0.05       7       0.06 0.07       6       97.9%       -0.12 [-0.19, -0.05]         Subtotal (95% Cl)       7       1.20       0.48       7       1.1%       -0.68 [-13,2.06]         Tawares-Silva 2021       0.33       0.71       7       1.20       84       10.0%       -0.33 [-101, 0.35]         Subtotal (95% Cl)       77       77       78       2.1%       -0.52 [-0.98, -0.07]	rest for overall effect:						-0.17 [-1.11, 0.77]	-
Subtotal (95% CI) 19 18 35.0% -1.31 [ $2.59$ , -0.03] Heterogeneity: Ch <sup>2</sup> = 1.056, df = 1 (P = 0.001); P = 91% Test for overall effect: Z = 2.00 (P = 0.05) Total (95% CI) 77 77 100.0% -0.57 [-1.33, 0.19] Heterogeneity: Ch <sup>2</sup> = 1.268, df = 3 (P = 0.005); P = 76% Test for overall effect: Z = 1.48 (P = 0.14) Test for subgroup differences: Ch <sup>2</sup> = 1.96, df = 1 (P = 0.16), P = 49.0% IL-10 Experimental Control Mean Difference Study or Subgroup Mean SD Total Mean SD Total Weight N. Fixed, 95% CI 1.12.1 IL-10 delayed to at least the next day of exercise Quero 2021 -0.06 0.05 7 0.08 0.07 6 97.9% -0.12 [-0.19, -0.05] Subtotal (95% CI) 7 6 97.9% -0.12 [-0.19, -0.05] Heterogeneity: Not applicable Test for overall effect Z = 3.50 (P = 0.0005) 1.12.2 IL-10 immediately after exercise Batatinha 2020 240.83 58 12 214.14 51.14 12 0.0% 26.69 [-17.06, 70.44] Pugh 2019 4.36 3.49 11 5.05 2.77 9 0.1% -0.68 [-1.32, -0.06] West 2011 0.33 0.71 7 1.02 0.48 7 1.1% -0.68 [-1.32, -0.06] West 2011 0.33 0.71 7 1.26 1.66 50 1.0% -0.33 [-1.01, 0.35] Subtotal (95% CI) 77 78 2.1% -0.52 [-0.98, -0.07] Heterogeneity: Ch <sup>2</sup> = 2.08, df = 3 (P = 0.56); P = 0% Test for overall effect Z = 3.79 (P = 0.0001) Total (95% CI) 84 84 100.0% -0.13 [-0.19, -0.06] Heterogeneity: Ch <sup>2</sup> = 5.01, df = 4 (P = 0.29); P = 20% Test for overall effect Z = 3.79 (P = 0.0001)		Z = 0.36 (P = 0.72)					-0.17 [-1.11, 0.77]	
Heterogeneity: Ch <sup>P</sup> = 10.56, df = 1 (P = 0.001); P = 91% Test for overall effect: Z = 2.00 (P = 0.05) Total (95% Cl) 77 77 100.0% -0.57 [-1.33, 0.19] Heterogeneity: Ch <sup>P</sup> = 12.68, df = 3 (P = 0.005); P = 76% Test for overall effect: Z = 1.48 (P = 0.14) Test for overall effect: Z = 1.48 (P = 0.14) Test for subgroup differences: Ch <sup>P</sup> = 1.96, df = 1 (P = 0.16), P = 49.0% LL-10 Experimental Control Mean Difference Study or Subgroup Mean SD Total Mean SD Total Weight N, Fixed, 95% Cl 1.12.1 L-10 delayed to at least the next day of exercise Quero 2021 -0.06 0.05 7 0.08 0.07 8 97.9% -0.12 [-0.19, -0.05] Subtotal (95% Cl) 7 6 97.9% -0.12 [-0.19, -0.05] Heterogeneity: Not applicable Test for overall effect: Z = 3.50 (P = 0.0005) 1.12.2 L-10 immediately after exercise Batalinha 2020 240.83 58 12 214.14 51.14 12 0.0% 26.69 [-17.06, 70.44] Pugh 2019 4.36 3.49 11 5.05 2.77 9 0.1% -0.69 [-3.43, 2.05] Heterogeneity: Chi <sup>P</sup> = 2.08, df = 3 (P = 0.56); P = 0% Test for overall effect: Z = 3.79 (P = 0.001) Test for overall effect: Z = 3.79 (P = 0.020) Total (95% Cl) 84 84 100.0% -0.13 [-0.19, -0.06] Heterogeneity: Chi <sup>P</sup> = 2.08, df = 3 (P = 0.56); P = 0% Test for overall effect: Z = 3.79 (P = 0.0001)	<b>1.8.2 IL-8 immediatel</b> Batatinha 2020	Z = 0.36 (P = 0.72) y after exercise 7.1 1.48	) 12 5.95	3.13		15.0%	1.15 (-0.81, 3.11)	
Total (95% Cl)       77       77       100.0%       -0.57 [-1.33, 0.19]         Heterogeneity: ChP = 12.68, df = 3 (P = 0.005); P = 76%       Test for overall effect: Z = 1.48 (P = 0.14)       Test for overall effect: Z = 1.48 (P = 0.14)       Favours [experimental]         Test for subgroup differences: ChP = 1.96, df = 1 (P = 0.16), P = 49.0%       Mean Difference       Mean Difference         L-10       Experimental       Control       Mean Difference       Mean Difference         Study or Subgroup       Mean SD       Total Weight       N. Fixed, 95% Cl       N. Fixed, 95% Cl         1.12.1 L-10 delayed to at least the next day of exercise       Mean Difference       Mean Difference       Mean Difference         Subtoral (95% Cl)       7       6       97.9%       -0.12 [-0.19, -0.05]       .0.12 [-0.19, -0.05]         Heterogeneity: Not applicable       7       0.05       2.77       9       0.1%       -0.69 [-3.43, 2.05]         Tavares-Silva 2021       0.33       0.71       7       1.02       0.48       7       1.1%       -0.69 [-3.43, 2.05]         Tavares-Silva 2021       0.33       0.71       7       1.26       1.0%       -0.31 [-0.19, -0.06]       .0.7         Weet 2011       0.93       1.75       47       1.26       1.66       50       1.0%	<b>1.8.2 IL-8 immediate!</b> Batatinha 2020 Quero-Calero 2022	Z = 0.36 (P = 0.72) y after exercise 7.1 1.48	) 12 5.95 7 5.04	3.13	6 3	15.0% 20.1% -	1.15 [-0.81, 3.11] -3.14 [-4.83, -1.45]	
Heterogeneity: $ChP = 12.69$ , $df = 3$ ( $P = 0.005$ ); $P = 76\%$ Test for overall effect $Z = 1.49$ ( $P = 0.14$ )         Fest for subgroup differences: $ChP = 1.96$ , $df = 1$ ( $P = 0.16$ ), $P = 49.0\%$ Heterogeneity: $ChP = 1.96$ , $df = 1$ ( $P = 0.16$ ), $P = 49.0\%$ Lip to the set the next day of exercise         Mean SD Total Mean SD Total Weight         N. Fixed, 95% CI         N. Fixed,	1.8.2 IL-8 immediate) Batatinha 2020 Quero-Calero 2022 Subtotal (95% Cl) Heterogeneity: Chi <sup>2</sup> =	Z = 0.36 (P = 0.72) y after exercise 7.1 1.48 1.9 1.23 10.56, df = 1 (P = 1	) 12 5.95 7 5.04 19 0.001); P= !	3.13 1.78	6 3	15.0% 20.1% -	1.15 [-0.81, 3.11] -3.14 [-4.83, -1.45]	
Test for overall effect: $Z = 1.48$ (P = 0.14) Test for subgroup differences: $Ch^{P} = 1.96$ , df = 1 (P = 0.16), P = 49.0% IL-10 Experimental Control Mean Difference Subtroal (95% Cl) - 7 6 97.9% -0.12 [-0.19, -0.05] Subtroal (95% Cl) - 7 6 97.9% -0.12 [-0.19, -0.05] Subtroal (95% Cl) - 7 6 97.9% -0.12 [-0.19, -0.05] Heterogeneity: Not applicable Test for overall effect Z = 3.50 (P = 0.0005) <b>1.12.2 IL</b> -10 immediately after exercise Batatinha 2020 240.83 58 12 214.14 51.14 12 0.0% 26.69 [-17.06, 70.44] Pugh 2019 4.36 3.49 11 5.05 2.77 9 0.1% -0.68 [-3.32, -0.06] West 2011 0.93 1.75 47 1.26 1.66 50 1.0% -0.33 [-1.01, 0.35] Subtroal (95% Cl) - 7 7 78 2.1% -0.52 [-0.98, -0.07] Heterogeneity: Chi <sup>P</sup> = 2.08, df = 3 (P = 0.56); I <sup>P</sup> = 0% Test for overall effect Z = 3.79 (P = 0.0001) Total (95% Cl) - 84 84 100.0% -0.13 [-0.19, -0.06] Heterogeneity: Chi <sup>P</sup> = 5.01, df = 4 (P = 0.29); I <sup>P</sup> = 20% Test for overall effect Z = 3.79 (P = 0.0001)	1.8.2 IL-8 immediate( Batatinha 2020 Quero-Calero 2022 Subtotal (95% Cl) Heterogeneity: Chi <sup>a</sup> = Test for overall effect:	Z = 0.36 (P = 0.72) y after exercise 7.1 1.48 1.9 1.23 10.56, df = 1 (P = 1	) 7 5.95 7 5.04 19 0.001); I <sup>a</sup> = ! )	3.13 1.78	6 18	15.0% 20.1% - 35.0% -	1.15 [-0.81, 3.11] 3.14 [-4.83, -1.45] 1.31 [-2.59, -0.03]	
Test for subgroup differences: $Ch^{\mu} = 1.96$ , $df = 1$ ( $P = 0.16$ ), $P = 4.9.0\%$ IL-10 Experimental Subty or Subgroup Mean SD Total Mean SD Total Weight IV, Fixed, 95% CI 1.12.1 IL-10 delayed to at least the next day of exercise Guero 2021 -0.06 0.05 7 0.08 0.07 6 97.9% -0.12 [-0.19, -0.05] Heterogeneity: Not applicable Test for overall effect Z = 3.50 ( $P = 0.0005$ ) 1.12.2 IL-10 immediately after exercise Batatinha 2020 240.83 58 12 214.14 51.14 12 0.0% 26.69 [-17.08, 70.44] Pugh 2019 4.36 3.49 11 5.05 2.77 9 0.1% -0.68 [-1.32, -0.06] Tavares-Silva 2021 0.33 0.71 7 1.02 0.48 7 1.1% -0.69 [-1.32, -0.06] West 2011 0.93 1.75 47 1.26 1.66 50 1.0% -0.33 [-1.01, 0.35] Subtotal (95% CI) Heterogeneity: Chi <sup>p</sup> = 2.08, df = 3 ( $P = 0.56$ ); $P = 0\%$ Test for overall effect Z = 3.79 ( $P = 0.0001$ ) Heterogeneity: Chi <sup>p</sup> = 5.01, df = 4 ( $P = 0.29$ ); $P = 20\%$ Test for overall effect Z = 3.79 ( $P = 0.0001$ ) Heterogeneity: Chi <sup>p</sup> = 5.01, df = 4 ( $P = 0.29$ ); $P = 20\%$	1.8.2 IL-8 immediatel Batatinha 2020 Quero-Calero 2022 Subtotal (95% CI) Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Total (95% CI)	Z = 0.36 (P = 0.72) y after exercise 7.1 1.48 1.9 1.23 10.58, df = 1 (P = 1 Z = 2.00 (P = 0.05)	) 12 5.95 7 5.04 19 0.001); P= 9 77	3.13 1.78 91%	6 18	15.0% 20.1% - 35.0% -	1.15 [-0.81, 3.11] 3.14 [-4.83, -1.45] 1.31 [-2.59, -0.03]	
Study or Subgroup         Mean SD Total Mean Mich Finder SD Total Weight INV, Fixed, 95% CI           Mean SD Total Mean SD Total Weight INV, Fixed, 95% CI           V. Fixed, 95% CI           1.12.1 L-10 delayed to at least the next day of exercise           Quero 2021         -0.06         0.05           Stubtotal (95% CI)         7         6         97.9%         -0.12 [-0.19, -0.05]           Heterogeneity, Not applicable           Test for overall effect Z = 3.50 (P = 0.0005)           1.12.2 L-10 immediately after exercise           Batatinha 2020         240.83         58         2           Batatinha 2020         240.83         58         1           Tavares-Silva 2021         0.33         0.71         7         9         0.1%         -0.06         West 2011         0.93         1.75         7         7         9         -1         0           West 2011         0.33         0.71         7 <t< td=""><td>1.8.2 IL-8 immediate Batatinha 2020 Quero-Calero 2022 Subtotal (95% CI) Heterogeneity: Chi<sup>a</sup> = Test for overall effect: Total (95% CI) Heterogeneity: Chi<sup>a</sup> = Test for overall effect:</td><td>Z = 0.36 (P = 0.72) y after exercise 7.1 1.48 1.9 1.23 10.56, df = 1 (P = 1 Z = 2.00 (P = 0.05) 12.68, df = 3 (P = 1 Z = 1.48 (P = 0.14)</td><td>) 12 5.95 7 5.04 19 0.001); P= ; ) 77 0.005); P= ; )</td><td>3.13 1.78 31%</td><td>6 18 77 1</td><td>15.0% 20.1% - 35.0% - 00.0%</td><td>1.15 [-0.81, 3.11] 3.14 [-4.83, -1.45] 1.31 [-2.59, -0.03]</td><td></td></t<>	1.8.2 IL-8 immediate Batatinha 2020 Quero-Calero 2022 Subtotal (95% CI) Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Total (95% CI) Heterogeneity: Chi <sup>a</sup> = Test for overall effect:	Z = 0.36 (P = 0.72) y after exercise 7.1 1.48 1.9 1.23 10.56, df = 1 (P = 1 Z = 2.00 (P = 0.05) 12.68, df = 3 (P = 1 Z = 1.48 (P = 0.14)	) 12 5.95 7 5.04 19 0.001); P= ; ) 77 0.005); P= ; )	3.13 1.78 31%	6 18 77 1	15.0% 20.1% - 35.0% - 00.0%	1.15 [-0.81, 3.11] 3.14 [-4.83, -1.45] 1.31 [-2.59, -0.03]	
1.12.1 IL-10 delayed to at least the next day of exercise         Quero 2021       -0.06       0.05       7       0.06       0.07       6       97.9%       -0.12 [-0.19, -0.05]         Subtotal (95% CI)       7       6       97.9%       -0.12 [-0.19, -0.05]       -0.12 [-0.19, -0.05]         Heterogeneity. Not applicable       -<	1.8.2 IL-8 immediate Batatinha 2020 Quero-Calero 2022 Subtotal (95% CI) Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Total (95% CI) Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Test for subgroup diff	Z = 0.36 (P = 0.72) y after exercise 7.1 1.48 1.9 1.23 10.56, df = 1 (P = 1 Z = 2.00 (P = 0.05) 12.68, df = 3 (P = 1 Z = 1.48 (P = 0.14)	) 12 5.95 7 5.04 19 0.001); P= ; ) 77 0.005); P= ; )	3.13 1.78 31%	6 18 77 1	15.0% 20.1% - 35.0% - 00.0%	1.15 [-0.81, 3.11] 3.14 [-4.83, -1.45] 1.31 [-2.59, -0.03]	
Subtotal (95% CI) 7 6 97.9% -0.12 [-0.19, -0.05] Heterogeneity: Not applicable Test for overall effect: Z = 3.50 ( $P = 0.0005$ ) 1.12.2 IL10 immediately after exercise Batatinha 2020 240.83 58 12 214.14 51.14 12 0.0% 26.59 [-17.06, 70.44] Pugh 2019 4.36 3.49 11 5.05 2.77 9 0.1% -0.69 [-3.43, 2.05] Tavares-Silva 2021 0.33 0.71 7 1.02 0.48 7 1.1% -0.68 [-3.43, 2.06] West 2011 0.93 1.75 47 1.26 1.66 50 1.0% -0.33 [-1.01, 0.35] Subtotal (95% CI) 77 78 2.1% -0.52 [-0.98, -0.07] Heterogeneity: Chi <sup>P</sup> = 2.08, df = 3 ( $P = 0.56$ ); $P = 0\%$ Test for overall effect: Z = 2.24 ( $P = 0.02$ ) Total (95% CI) 84 84 100.0% -0.13 [-0.19, -0.06] Heterogeneity: Chi <sup>P</sup> = 5.01, df = 4 ( $P = 0.29$ ); $P = 20\%$ Test for overall effect: Z = 3.79 ( $P = 0.0001$ )	1.8.2 IL-8 immediate Batatinha 2020 Quero-Calero 2022 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Total (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Test for overall effect: Test for subgroup diff	Z = 0.36 (P = 0.72) y after exercise 7.1 1.48 1.9 1.23 10.56, df = 1 (P = 1) Z = 2.00 (P = 0.05) 12.68, df = 3 (P = 1) z = 1.48 (P = 0.14) Experimental	) 12 5.95 7 5.04 19 0.001);  * = 9 77 0.005);  * = 1 96, df = 1 (P	3.13 1.78 31% 76% = 0.16), control	6 : 18 77 1 F = 49.0	15.0% 20.1% - 35.0% - 00.0%	1.15 [-0.81, 3.11] -3.14 [-4.83, -1.45] -1.31 [-2.59, -0.03] -0.57 [-1.33, 0.19] - Mean Difference	Favours (experimental) Favours (control) Mean Difference
Heterogeneity: Not applicable Test for overall effect Z = $3.50$ (P = 0.0005) <b>1.12.2 IL-10 immediately after exercise</b> Batatinha 2020 240.83 58 12 214.14 51.14 12 0.0% 26.69 [-17.06, 70.44] Pugh 2019 4.36 3.49 11 5.05 2.77 9 0.1% -0.69 [-3.43, 2.05] Tavares-Silva 2021 0.33 0.71 7 1.02 0.48 7 1.1% -0.69 [-1.32, -0.06] West 2011 0.93 1.75 47 1.26 1.66 50 1.0% -0.33 [-1.01, 0.35] Subtotal (95% Ct) 77 78 2.1% -0.52 [-0.98, -0.07] Heterogeneity: Chi <sup>P</sup> = 2.08, df = 3 (P = 0.56); I <sup>P</sup> = 0% Test for overall effect Z = 2.24 (P = 0.29); I <sup>P</sup> = 20% Heterogeneity: Chi <sup>P</sup> = 5.01, df = 4 (P = 0.29); I <sup>P</sup> = 20% Heterogeneity: Chi <sup>P</sup> = 5.01, df = 4 (P = 0.29); I <sup>P</sup> = 20% Test for overall effect Z = 3.79 (P = 0.0001)	1.8.2 IL-8 immediate Batatinha 2020 Quero-Calero 2022 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Total (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Test for subgroup diff IL-10 Study or Subgroup	Z = 0.36 (P = 0.72) y after exercise 7.1 1.48 1.9 1.23 10.56, df = 1 (P = 1 Z = 2.00 (P = 0.05) 12.68, df = 3 (P = 1 Z = 1.48 (P = 0.14) Experimental Mean SD To	) 12 5.95 7 5.04 19 0.001); F = 1 0 77 77 0.005); F = 1 0 66, df = 1 (P C tal Mean	3.13 1.78 31% 76% = 0.16), somtrol SD	6 : 18 77 1 F = 49.0	15.0% 20.1% - 35.0% - 00.0%	1.15 [-0.81, 3.11] -3.14 [-4.83, -1.45] -1.31 [-2.59, -0.03] -0.57 [-1.33, 0.19] - Mean Difference	Favours (experimental) Favours (control) Mean Difference
Batatinha 2020 240.83 58 12 214.14 51.14 12 0.0% 26.69 [-17.06, 70.44] Pugh 2019 4.36 3.49 11 5.05 2.77 9 0.1% -0.69 [-1.32, -0.06] Tavares-Silva 2021 0.33 0.71 7 1.02 0.48 7 1.1% -0.69 [-1.32, -0.06] West 2011 0.93 1.75 47 1.26 1.66 50 1.0% -0.33 [-1.01, 0.35] Subtotal (95% Cl) 77 78 2.1% -0.52 [-0.98, -0.07] Heterogeneity: Chi <sup>p</sup> = 2.08, df = 3 (P = 0.56); <sup>p</sup> = 0% Test for overall effect Z = 3.79 (P = 0.001) Favours lexperimental Favours lexpe	1.8.2 IL-8 immediate Batatinha 2020 Quero-Calero 2022 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Total (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Test for subgroup diff IL-10 <u>Study or Subgroup</u> 1.12.1 IL-10 delayed to Quero 2021	Z = 0.36 (P = 0.72) y after exercise 7.1 1.48 1.9 1.23 10.56, df = 1 (P = 1 Z = 2.00 (P = 0.05) 12.68, df = 3 (P = 1 Z = 1.48 (P = 0.14) erences: Chi <sup>P</sup> = 1.3 Experimental Mean SD To o al least the next	) 12 5.95 7 5.04 19 0.001); F = 1 ) 77 77 36, df = 1 (F C tal Mean day of exer	3.13 1.78 31% 76% = 0.16), control SD cise	6 : 18 77 1 I <sup>2</sup> = 49.0 <u>Total V</u> 6	15.0% 20.1% - 35.0% - 00.0% 0% Weight 97.9%	1.15 [-0.81, 3.11] 3.14 [-4.83, -1.45] 1.31 [-2.59, -0.03] -0.57 [-1.33, 0.19] - Mean Difference N, Fixed, 95% Cl -0.12 [-0.19, -0.05]	Favours (experimental) Favours (control) Mean Difference
Pugh 2019       4.36       3.49       11       5.05       2.77       9       0.1% $-0.69 [-3.43, 2.05]$ Tavares-Silva 2021       0.33       0.71       7       1.02       0.48       7       1.1% $-0.69 [-3.43, 2.05]$ West 2011       0.33       1.75       47       1.26       1.66       50       1.0% $-0.33 [-1.01, 0.35]$ Subtotal (95% CI)       77       78       2.1% $-0.52 [-0.98, -0.07]$ Heterogeneity. Chi <sup>p</sup> = 2.08, df = 3 (P = 0.56); P = 0.0%       78       2.1% $-0.52 [-0.98, -0.07]$ Total (95% CI)       84       100.0% $-0.13 [-0.19, -0.06]$ $-2$ $-1$ $0$ $2$ Test for overall effect Z = 3.79 (P = 0.0001)       54       100.0% $-0.13 [-0.19, -0.06]$ $-2$ $-1$ $0$ $2$ Featoring termental effect Z = 3.79 (P = 0.0001)       54       52 $-2$ $-1$ $0$ $1$ $2$ Featoring termental effect Z = 3.79 (P = 0.0001)       54 $-2$ $-1$ $0$ $1$ $2$	1.8.2 IL-8 immediate Batatinha 2020 Quero-Calero 2022 Subtotal (95% CI) Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Total (95% CI) Heterogeneity: Chi <sup>a</sup> = Test for overall effect Test for subgroup diff [L-10 <u>Study or Subgroup</u> 1.12.1 IL-10 delayed to Quero 2021 Subtotal (95% CI) Heterogeneity: Not app	Z = 0.36 (P = 0.72) y after exercise 7.1 1.48 1.9 1.23 10.56, df = 1 (P = 1 Z = 2.00 (P = 0.05) 12.68, df = 3 (P = 1) Z = 1.48 (P = 0.14) erences: Chi <sup>P</sup> = 1.1 Experimental Mean SD To o at least the next -0.06 0.05 plicable	) 12 5.95 7 5.04 19 0.001); F = 1 ) 77 0.005); F = 1 ) 96, df = 1 (F C tal Mean day of exer 7 0.08 7	3.13 1.78 31% 76% = 0.16), control SD cise	6 : 18 77 1 I <sup>2</sup> = 49.0 <u>Total V</u> 6	15.0% 20.1% - 35.0% - 00.0% 0% Weight 97.9%	1.15 [-0.81, 3.11] 3.14 [-4.83, -1.45] 1.31 [-2.59, -0.03] -0.57 [-1.33, 0.19] - Mean Difference N, Fixed, 95% Cl -0.12 [-0.19, -0.05]	Favours (experimental) Favours (control) Mean Difference
Tavares-Silva 2021       0.33       0.71       7       1.02       0.48       7       1.1% $-0.69 \downarrow 1.32, -0.06 j$ West 2011       0.93       1.75       47       1.26       1.66       50       1.0% $-0.33 \downarrow 1.01, 0.36 j$ Subtotal (95% Cl)       77       78       2.1% $-0.52 \downarrow 0.98, -0.07 j$ $-0.33 \downarrow 1.01, 0.36 j$ Heterogeneity, Chil <sup>2</sup> = 2.08, df = 3 (P = 0.56); l <sup>2</sup> = 0%       78       2.1% $-0.52 \downarrow 0.98, -0.07 j$ Total (95% Cl)       84       84       100.0% $-0.13 \downarrow 0.19, -0.06 j$ Heterogeneity, Chil <sup>2</sup> = 5.01, df = 4 (P = 0.29); l <sup>2</sup> = 20% $-2$ $-1$ $0$ $1$ Test for overail effect Z = 3.79 (P = 0.0001)       Favours legrentimental       Favours legrentingth       Favours legrentingth	1.8.2 IL-8 immediate Batatinha 2020 Quero-Calero 2022 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Total (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for subgroup diff [L-10 <u>Study or Subgroup</u> 1.12.1 IL-10 delayed to Quero 2021 Subtotal (95% CI) Heterogeneity: Not ap Test for overall effect 2	Z = 0.36 (P = 0.72) y after exercise 7.1 1.48 1.9 1.23 10.56, df = 1 (P = 1 Z = 2.00 (P = 0.05) 12.68, df = 3 (P = 1 Z = 1.48 (P = 0.14) erences: ChP = 1.1 Experimental Mean SD To o at least the next -0.06 0.05 plicable Z = 3.50 (P = 0.000	) 12 5.95 7 5.04 19 0.001); F = 1 ) 77 0.005); F = 1 ) 96, df = 1 (F C tal Mean day of exer 7 0.08 7	3.13 1.78 31% 76% = 0.16), control SD cise	6 : 18 77 1 I <sup>2</sup> = 49.0 <u>Total V</u> 6	15.0% 20.1% - 35.0% - 00.0% 0% Weight 97.9%	1.15 [-0.81, 3.11] 3.14 [-4.83, -1.45] 1.31 [-2.59, -0.03] -0.57 [-1.33, 0.19] - Mean Difference N, Fixed, 95% Cl -0.12 [-0.19, -0.05]	Favours (experimental) Favours (control) Mean Difference
West 2011       0.93       1.75       47       1.26       1.66       50       1.0% $-0.33[+1.01, 0.35]$ Subtotal (95% CI)       77       78       2.1% $-0.33[+1.01, 0.35]$ Heterogeneity: Chi <sup>P</sup> = 2.08, df = 3 (P = 0.56); I <sup>P</sup> = 0%       78       2.1% $-0.52[-0.98, -0.07]$ Total (95% CI)       84       84       100.0% $-0.13[-0.19, -0.06]$ Heterogeneity: Chi <sup>P</sup> = 5.01, df = 4 (P = 0.29); I <sup>P</sup> = 20%       -2 $-1$ 0       1         Test for overall effect: Z = 3.79 (P = 0.0001)       Favours legeneimentall       Favours legeneimentall       Favours legeneimentall	1.8.2 IL-8 immediate Batatinha 2020 Quero-Calero 2022 Subtotal (95% Cl) Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Total (95% Cl) Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Test for subgroup dif IL-10 <u>Study or Subgroup</u> 1.12.1 IL-10 delayed to Quero 2021 Subtotal (95% Cl) Heterogeneity: Not ap Test for overall effect : 1.12.2 IL-10 immediat	Z = 0.36 (P = 0.72) y after exercise 7.1 1.48 1.9 1.23 10.56, df = 1 (P = 1) Z = 2.00 (P = 0.05) 12.69, df = 3 (P = 1) Z = 1.48 (P = 0.14) erences: Chi <sup>P</sup> = 1.1 Experimental Mean SD To o at least the next -0.06 0.05 plicable Z = 3.50 (P = 0.000) ely after exercise	) 12 5.95 7 5.04 19 0.001); I <sup>a</sup> = 1 ) 77 77 77 77 0.005); I <sup>a</sup> = 1 ) 36, df = 1 (P <u>c</u> tal <u>Mean</u> day of exer 7 0.08 7 5)	3.13 1.78 31% 76% = 0.16), control SD cise 0.07	6 18 77 1 I <sup>a</sup> = 49.0 <u>Total V</u> 6 6	15.0% 20.1% 35.0% 00.0% 0% Weight 97.9% 97.9%	1.15 [-0.81, 3.11] 3.14 [-4.83, -1.45] 1.31 [-2.59, -0.03] -0.57 [-1.33, 0.19] - - - - - - - - - - - - - - - - - - -	Favours (experimental) Favours (control) Mean Difference
Subtotal (95% Cl)         77         78         2.1%         -0.52 [-0.98, -0.07]           Heterogeneity: Chil* = 2.08, df = 3 (P = 0.56); l* = 0%         Test for overall effect Z = 2.24 (P = 0.02)         Image: Chil* = 5.01, df = 4 (P = 0.29); l* = 20%         Events for overall effect Z = 3.79 (P = 0.0001)           Total (95% Cl)         84         100.0%         -0.13 [-0.19, -0.06]         Image: Chil* = 5.01, df = 4 (P = 0.29); l* = 20%           Test for overall effect Z = 3.79 (P = 0.0001)         Favours (Evention to 1)         Image: Chil* = 5.01, df = 4 (P = 0.0001)	1.8.2 IL-8 immediate Batatinha 2020 Quero-Calero 2022 Subtotal (95% CI) Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Total (95% CI) Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Test for subgroup diff IL-10 <u>Study or Subgroup</u> 1.12.1 IL-10 delayed to Quero 2021 Subtotal (95% CI) Heterogeneity: Not ap Test for overall effect : 1.12.2 IL-10 immediat Batatinha 2020 Pugh 2019	Z = 0.36 ( $P$ = 0.72) y after exercise 7.1 1.48 1.9 1.23 10.56, df = 1 ( $P$ = 1 Z = 2.00 ( $P$ = 0.05 12.68, df = 3 ( $P$ = 1 Z = 1.48 ( $P$ = 0.14 erences: Chi <sup>P</sup> = 1.1 Experimental Mean SD To o at least the next -0.06 0.05 plicable Z = 3.50 ( $P$ = 0.000 ey after exercise 240.83 58 4.36 3.49	12 5.95 7 5.04 19 0.001); ℙ = : ) 36, df = 1 (P C C tal Mean day of exer 7 0.06 7 5 5 12 214.14 11 5.05	3.13 1.78 31% = 0.16), omtrol SD ccise 0.07 51.14 2.77	6 18 77 1 F <sup>*</sup> = 49.0 Total V 6 6 6	15.0% 20.1% - 35.0% - 00.0% 00.0% 97.9% 97.9% 97.9% 0.0% :	1.15 [-0.81, 3.11] 3.14 [-4.83, -1.45] 1.31 [-2.59, -0.03] -0.57 [-1.33, 0.19] -0.57 [-1.33, 0.19] -0.57 [-1.33, 0.19] -0.12 [-0.19, -0.05] -0.12 [-0.19, -0.05] 26.69 [-17.06, 70.44] -0.69 [-3.43, 2.05]	Favours (experimental) Favours (control) Mean Difference
Heterogeneity: Chi <sup>p</sup> = 2.08, df = 3 (P = 0.56); i <sup>p</sup> = 0% Test for overall effect: Z = 2.24 (P = 0.02) Total (95% Cl) 84 84 100.0% -0.13 [-0.19, -0.06] Heterogeneity: Chi <sup>p</sup> = 5.01, df = 4 (P = 0.29); i <sup>p</sup> = 20% Test for overall effect: Z = 3.79 (P = 0.001) Favours (experimental Experimental Exper	1.8.2 IL-8 immediate Batatinha 2020 Quero-Calero 2022 Subtotal (95% CI) Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Total (95% CI) Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Test for subgroup dif IL-10 <u>Study or Subgroup dif</u> UL-10 <u>Study or Subgroup dif</u> UL-10 Subtotal (95% CI) Heterogeneity: Not ap Test for overall effect : 1.12.2 IL-10 immediat Batatinha 2020 Pugh 2019 Tavares-Silva 2021	Z = 0.36 (P = 0.72) y after exercise 7.1 1.48 1.9 1.23 10.56, df = 1 (P = 1 Z = 2.00 (P = 0.05) 12.68, df = 3 (P = 1 Z = 1.48 (P = 0.14) erences: ChP = 1.1 Experimental Mean SD To o at least the next -0.06 0.05 plicable Z = 3.50 (P = 0.000 ety after exercise 240.83 58 4.36 3.49 0.33 0.71	) 12 5.95 7 5.04 19 0.001); P = ± ) 77 77 77 77 0.005); P = ± ) 36, df = 1 (P C tal Mean day of exer 7 0.08 7 5) 12 214.14 11 5.05 7 1.02	3.13 1.78 31% 76% = 0.16), sontrol SD cise 0.07 51.14 2.77 0.48	6 18 77 1 I <sup>2</sup> = 49.0 <u>Total V</u> 6 6 6	15.0% 20.1% - 35.0% - 00.0% 9% 97.9% 97.9% 97.9% 97.9% 97.9% 97.9% 1.1%	1.15 [-0.81, 3.11] 3.14 [-4.83, -1.45] 1.31 [-2.59, -0.03] -0.57 [-1.33, 0.19] -0.57 [-1.33, 0.19] -0.57 [-1.33, 0.19] -0.59 [-1.33, 0.05] -0.12 [-0.19, -0.05] -0.12 [-0.19, -0.05] -0.69 [-1.32, -0.06] -0.69 [-1.32, -0.06]	Favours (experimental) Favours (control) Mean Difference
Total (95% CI)         84         84         100.0%         -0.13 [-0.19, -0.06]           Heterogeneity: ChiP = 5.01, df = 4 (P = 0.29); P = 20%         -2         -1         0         1         2           Test for overall effect: Z = 3.79 (P = 0.0001)         Favours [experimental]         Favours [experimental]         Favours [experimental]	1.8.2 IL-8 immediate Batatinha 2020 Quero-Calero 2022 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Total (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Test for subgroup 1.12.1 IL-10 delayed to Quero 2021 Subtotal (95% CI) Heterogeneity: Not ap Test for overall effect : 1.12.2 IL-10 immediat Batatinha 2020 Pugh 2019 Tavares-Silva 2021 West 2011	Z = 0.36 ( $P = 0.72$ ) y after exercise 7.1 1.48 1.9 1.23 10.56, df = 1 ( $P = 1$ Z = 2.00 ( $P = 0.05$ ) 12.68, df = 3 ( $P = 1$ Z = 1.48 ( $P = 0.14$ ) terences: Chi <sup>P</sup> = 1.3 Experimental Mean SD To o at least the next -0.06 0.05 plicable Z = 3.50 ( $P = 0.000$ ety after exercise 4.36 3.49 0.33 0.71 0.93 1.75	12 5.95 7 5.04 19 0.001); ℙ = ! ) 77 0.005); ℙ = : ) 36, df = 1 (ℙ 27 0.05 7 0.05 7 12 214.14 11 5.05 7 1.02 47 1.26	3.13 1.78 31% 76% = 0.16), sontrol SD cise 0.07 51.14 2.77 0.48	6 18 77 1 1 <sup>a</sup> = 49.0 <u>Total V</u> 6 6 12 9 7 50	15.0% 20.1% 35.0% 35.0% 400.0% 97.9% 97.9% 97.9% 0.1% 1.1% 1.0%	1.15 [-0.81, 3.11] 3.14 [-4.83, -1.45] 1.31 [-2.59, -0.03] -0.57 [-1.33, 0.19] - Mean Difference IV, Fixed, 95% Cl -0.12 [-0.19, -0.05] -0.12 [-0.19, -0.05] -0.12 [-0.19, -0.05] -0.68 [-1.7.06, 70.44] -0.68 [-1.32, -0.06] -0.33 [-1.01, 0.35]	Favours (experimental) Favours (control) Mean Difference
Heterogeneity: ChIP = 5.01, df = 4 (P = 0.29); IP = 20% Test for overall effect: Z = 3.79 (P = 0.0001) Favours (control)	1.8.2 IL-8 immediate Batatinha 2020 Quero-Calero 2022 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Total (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for subgroup diff IL-10 <u>Study or Subgroup</u> 1.12.1 IL-10 delayed to Quero 2021 Subtotal (95% CI) Heterogeneity: Not app Tayares-Silva 2020 Pugh 2019 Tayares-Silva 2021 West 2011 Subtotal (95% CI)	Z = 0.36 (P = 0.72) y after exercise 7.1 1.48 1.9 1.23 10.56, df = 1 (P = 1 Z = 2.00 (P = 0.05) 12.68, df = 3 (P = 1) Z = 1.48 (P = 0.14) erences: ChP = 1.1 Experimental Mean SD To o at least the next -0.06 0.05 plicable Z = 3.50 (P = 0.000 ety after exercise 240.83 58 4.36 3.49 0.33 0.71 0.33 0.71 0.93 1.75 2.09, df = 3 (P = 0.5)	12 5.95 7 5.04 19 0.001); ℙ = : ) 36, df = 1 (P C tal Mean day of exer 7 0.08 7 5) 12 214.14 1 5.05 7 1.02 47 1.26 77	3.13 1.78 31% 76% = 0.16), sontrol SD cise 0.07 51.14 2.77 0.48	6 18 77 1 1 <sup>a</sup> = 49.0 <u>Total V</u> 6 6 12 9 7 50	15.0% 20.1% - 35.0% - 00.0% 0% <u>Weight</u> 97.9% 97.9% 1.1% 1.1%	1.15 [-0.81, 3.11] 3.14 [-4.83, -1.45] 1.31 [-2.59, -0.03] -0.57 [-1.33, 0.19] - Mean Difference IV, Fixed, 95% Cl -0.12 [-0.19, -0.05] -0.12 [-0.19, -0.05] -0.12 [-0.19, -0.05] -0.68 [-1.7.06, 70.44] -0.68 [-1.32, -0.06] -0.33 [-1.01, 0.35]	Favours (experimental) Favours (control) Mean Difference
Test for overall effect: Z = 3.79 (P = 0.0001) $-2$ $-1$ $2$ Favours lexperimentall Favours (control)	1.8.2 IL-8 immediate Batatinha 2020 Quero-Calero 2022 Subtotal (95% CI) Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Total (95% CI) Heterogeneity: Chi <sup>a</sup> = Test for subgroup dif IL-10 <u>Study or Subgroup dif</u> IL-10 <u>Study or Subgroup dif</u> L1.2.1 IL-10 delayed to Quero 2021 Subtotal (95% CI) Heterogeneity: Not ap Test for overall effect : 1.12.2 IL-10 immediat Batatinha 2020 Pugh 2019 Tavarse-Silva 2021 West 2011 Subtotal (95% CI) Heterogeneity: Chi <sup>a</sup> = Test for overall effect :	Z = 0.36 (P = 0.72) y after exercise 7.1 1.48 1.9 1.23 10.56, df = 1 (P = 1 Z = 2.00 (P = 0.05) 12.68, df = 3 (P = 1) Z = 1.48 (P = 0.14) erences: ChP = 1.1 Experimental Mean SD To o at least the next -0.06 0.05 plicable Z = 3.50 (P = 0.000 ety after exercise 240.83 58 4.36 3.49 0.33 0.71 0.93 1.75 2.08, df = 3 (P = 0.5) Z = 2.24 (P = 0.02)	) 12 5.95 7 5.04 19 0.001); P = : ) 77 77 77 0.005); P = : ) 36, df = 1 (P C tal Mean day of exer 7 0.08 7 5) 12 214.14 1 5.05 7 1.26 77 7.026 7 1.26 77 1.26 77 7.05 7 1.26 7 1.26 77 7.05 7 1.26 7 1.26 77 7.05 7 1.26 7 1.26 7 7 7 .05 7 1.26 7 1.26 7 7 7 .05 7 1.26 7 7 7 .05 7 .05 7 1.26 7 7 7 .05 7	3.13 1.78 31% 76% = 0.16), sontrol SD cise 0.07 51.14 2.77 0.48	6 : 18 - 77 1 1 <sup>2</sup> = 49.0 Total V 6 6 6 12 9 7 50 50 78	15.0% 20.1% 35.0% 35.0% 00.0% 97.9% 97.9% 97.9% 97.9% 0.0% 1.1% 1.0% 2.1%	1.15 [-0.81, 3.11] 3.14 [-4.83, -1.45] 1.31 [-2.59, -0.03] -0.57 [-1.33, 0.19] -0.57 [-1.33, 0.19] -0.57 [-1.33, 0.19] -0.12 [-0.19, -0.05] -0.12 [-0.19, -0.05] -0.12 [-0.19, -0.05] -0.69 [-1.32, -0.06] -0.39 [-1.32, -0.06] -0.33 [-1.01, 0.35] -0.52 [-0.98, -0.07]	Favours (experimental) Favours (control) Mean Difference
	1.8.2 IL-8 immediatel Batatinha 2020 Quero-Calero 2022 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Total (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for subgroup diff IL-10 <u>Study or Subgroup</u> 1.12.1 IL-10 delayed to Quero 2021 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect i 1.12.2 IL-10 immediat Batatinha 2020 Pugh 2019 Tavares-Silva 2021 West 2011 Subtotal (95% CI)	Z = 0.36 ( $P = 0.72$ ) y after exercise 7.1 1.48 1.9 1.23 10.56, df = 1 ( $P = 1$ ) Z = 2.00 ( $P = 0.05$ ) 12.68, df = 3 ( $P = 1$ ) Z = 1.48 ( $P = 0.14$ ) erences: ChP = 1.3 Experimental Mean SD To o at least the next -0.06 0.05 plicable Z = 3.50 ( $P = 0.000$ ely after exercise 240.83 58 4.36 3.49 0.33 0.71 0.33 0.71 0.33 1.75 2.08, df = 3 ( $P = 0.52$ )	12 5.95 7 5.04 19 0.001); F = 1 77 0.005); F = 1 96, df = 1 (F C tal Mean day of exer 7 0.08 7 12 214.14 11 5.05 7 0.08 7 5) 12 214.14 11 5.05 7 1.02 47 1.26 77 84 84	3.13 1.78 31% 76% 76% 76% 76% 76% 50.16), 50.16), 51.14 2.77 0.48 1.66	6 : 18 - 77 1 1 <sup>2</sup> = 49.0 Total V 6 6 6 12 9 7 50 50 78	15.0% 20.1% 35.0% 35.0% 00.0% 97.9% 97.9% 97.9% 97.9% 0.0% 1.1% 1.0% 2.1%	1.15 [-0.81, 3.11] 3.14 [-4.83, -1.45] 1.31 [-2.59, -0.03] -0.57 [-1.33, 0.19] -0.57 [-1.33, 0.19] -0.57 [-1.33, 0.19] -0.12 [-0.19, -0.05] -0.12 [-0.19, -0.05] -0.12 [-0.19, -0.05] -0.69 [-1.32, -0.06] -0.39 [-1.32, -0.06] -0.33 [-1.01, 0.35] -0.52 [-0.98, -0.07]	Favours (experimental) Favours (control)  Mean Difference IV, Fixed, 95% CI
	1.8.2 IL-8 immediate Batatinha 2020 Quero-Calero 2022 Subtotal (95% CI) Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Total (95% CI) Heterogeneity: Chi <sup>a</sup> = Test for overall effect Test for subgroup diff IL-10 <u>Study or Subgroup</u> 1.12.1 IL-10 delayed t Quero 2021 Subtotal (95% CI) Heterogeneity: Chi <sup>a</sup> = Test for overall effect 2 1.12.2 IL-10 immediat Batatinha 2020 Pugh 2019 Tavares-Silva 2021 West-2011 Subtotal (95% CI) Heterogeneity: Chi <sup>a</sup> = 1 Test for overall effect 2 Total (95% CI)	Z = 0.36 ( $P = 0.72$ ) y after exercise 7.1 1.48 1.9 1.23 10.56, df = 1 ( $P = 1$ Z = 2.00 ( $P = 0.05$ ) 12.68, df = 3 ( $P = 1$ . Z = 1.48 ( $P = 0.14$ erences: Chi <sup>P</sup> = 1.1 Experimental Mean SD To o at least the next -0.06 0.05 plicable Z = 3.50 ( $P = 0.005$ ) plicable 240.83 58 4.36 3.49 0.33 0.71 0.93 1.75 2.08, df = 3 ( $P = 0.5$ Z = 2.24 ( $P = 0.22$ ) 5.01, df = 4 ( $P = 0.2$	12 5.95 7 5.04 19 .0.01); ℙ = : ) 77 77 .0.005); ℙ = : ) 36, df = 1 (P C C C C C C C C C C C C C	3.13 1.78 31% 76% 76% 76% 76% 76% 50.16), 50.16), 51.14 2.77 0.48 1.66	6 : 18 - 77 1 1 <sup>2</sup> = 49.0 Total V 6 6 6 12 9 7 50 50 78	15.0% 20.1% 35.0% 35.0% 00.0% 97.9% 97.9% 97.9% 97.9% 0.0% 1.1% 1.0% 2.1%	1.15 [-0.81, 3.11] 3.14 [-4.83, -1.45] 1.31 [-2.59, -0.03] -0.57 [-1.33, 0.19] -0.57 [-1.33, 0.19] -0.57 [-1.33, 0.19] -0.12 [-0.19, -0.05] -0.12 [-0.19, -0.05] -0.12 [-0.19, -0.05] -0.69 [-1.32, -0.06] -0.39 [-1.32, -0.06] -0.33 [-1.01, 0.35] -0.52 [-0.98, -0.07]	Favours (experimental) Favours (control) Mean Difference IV, Fixed, 95% Cl

**Figure 6.** Forest plots of the mean effect size for the subgroups with sample collection delayed to at least the next day of exercise and immediately performed after exercise for (**a**) TNF $-\alpha$ , (**b**) IL-6, (**c**) IL-8, and (**d**) IL-10.

In the subgroup analysis based on the timing of postintervention blood sampling, the subgroup whose blood sample collection was delayed to at least the next day of exercise exhibited a significant negative change in the IL-10 level compared with the control group, with an effect size of -0.12 (95% Cl: -0.19, -0.05, p = 0.0005). The subgroup whose blood

13 of 21

samples were collected immediately after exercise demonstrated a significant negative change in the IL-10 level compared with the control group in the fixed-effect model, with an effect size of -0.52 (95% Cl: -0.98, -0.07, p = 0.02; heterogeneity: chi-square = 2.08, df = 3, p = 0.56,  $I^2 = 0\%$ ; Figure 6d).

# 3.10. Outcome of IFN- $\gamma$

The effect size of two RCTs for the outcome of IFN- $\gamma$  was 14.33 (95% Cl: 13.76, 14.89, p < 0.00001; heterogeneity: chi-square = 33.78, df = 1, p < 0.00001, I<sup>2</sup> = 97%). The probiotic group exhibited a significant positive change in the IFN- $\gamma$  level compared with the control group (Figure 4e).

# 3.11. Outcome of Salivary IgA

The effect size of two RCTs for the outcome of salivary IgA was 3.57 (95% Cl: 0.66, 6.48, p = 0.02; heterogeneity: chi-square = 0.29, df = 1, p = 0.59,  $I^2 = 0$ %). The probiotic group demonstrated a significant positive change in the salivary IgA level compared with the control group (Figure 4f).

# 3.12. Outcome of IL-1 $\beta$

The effect size of two RCTs for the outcome of IL-1 $\beta$  was -0.03 (95% Cl: -0.14, 0.08, p = 0.62; heterogeneity: chi-square = 5.67, df = 1, p = 0.02, I<sup>2</sup> = 82%). The probiotic group exhibited no significant positive change in the IL-1 $\beta$  level compared with the control group (Figure 4g).

# 3.13. Outcome of IL-2

The effect size of two RCTs for the outcome of IL-2 was -0.04 (95% Cl: -0.38, 0.31, p = 0.83; heterogeneity: chi-square = 0.99, df = 1, p = 0.32,  $I^2 = 0$ %). The probiotic group exhibited no significant positive change in the IL-2 level compared with the control group (Figure 4h).

# 3.14. Outcome of IL-4


The effect size of two RCTs for the outcome of IL-4 was -0.14 (95% Cl: -1.05, 0.77, p = 0.76; heterogeneity: chi-square = 0.25, df = 1, p = 0.62,  $I^2 = 0$ %). The probiotic group demonstrated no significant positive change in the IL-4 level compared with the control group (Figure 4i).

# 3.15. Outcome of CRP

The effect size of two RCTs for the outcome of CRP was -0.69 (95% Cl: -2.51, 1.13, p = 0.46; heterogeneity: chi-square = 2.70, df = 1, p = 0.10,  $I^2 = 63\%$ ). The probiotic group demonstrated no significant positive change in the CRP level compared with the control group (Figure 4j).

# 3.16. Publication Bias

According to the funnel plots (Figure 7), no heterogeneity was noted for the outcomes of IL-6 (Figure 7b), salivary IgA (Figure 7f), IL-2 (Figure 7h), and IL-4 (Figure 7i) because the included studies appeared to be distributed within two diagonal lines representing their pseudo 95% confidence limits. However, for the outcomes of IL-8 (Figure 7c), IFN- $\gamma$  (Figure 7e), and IL-1 $\beta$  (Figure 7g), the studies appeared to be distributed beyond two diagonal lines representing heterogeneity [48].



**Figure 7.** Funnel plots of included studies: (a) TNF $-\alpha$ , (b) IL-6, (c) IL-8, (d) IL-10, (e) IFN $-\gamma$ , (f) salivary IgA, (g) IL $-1\beta$ , (h) IL-2, (i) IL-4, and (j) CRP.

# 4. Discussion

# 4.1. Overall Effect

To the best of our knowledge, this is the first meta-analysis to investigate the effects of probiotic supplementation on the levels of inflammation-related markers, namely IL-1 $\beta$ , IL-2, IL-4, IL-6, IL-8, IL-10, TNF- $\alpha$ , IFN- $\gamma$ , CRP, and salivary IgA, in athletes.

A study reported that the consumption of a symbiotic bacterium did not affect immuneand inflammation-related markers in athletes [25]. Pugh et al. indicated that the IL-6, IL-8, and IL-10 levels were not significantly different before or after the race between the placebo and probiotic groups, although athletes self-reported lower incidence and severity of gastrointestinal tract symptoms [23]. Schreiber et al. demonstrated that the mean IL-6, TNF- $\alpha$ , and CRP levels were not affected by probiotics [20].

Conversely, some studies have reported the beneficial effects of probiotics. Smarkusz-Zarzecka et al. observed that the TNF- $\alpha$  level was lower in both sexes after probiotic supplementation [22]. Tavares-Silva et al. noted a significant decline in the IL-2 and IL-4 levels 24 h before exercise in the probiotic group compared with the placebo group [21]. West et al. indicated that probiotic supplementation attenuated acute exercise-induced changes in both anti-inflammatory and proinflammatory cytokines (IL-6, IL-8, IL-10, IFN- $\gamma$ , and TNF- $\alpha$ ) in male and female athletes [8].

Moderate activity may enhance immune function to higher than that noted at the sedentary level, whereas intense exercise may cause oxidative stress, muscle damage, inflammation, and immune alteration in elite athletes, leading to upper respiratory tract and gastrointestinal tract illness, especially diarrhea, during heavy training and competitions such as marathons [1–4,50,51]. In our meta-analysis, we examined the effects of probiotic supplementation on the levels of proinflammatory and anti-inflammatory cytokines in athletes at baseline and after probiotics supplementation. The findings of this meta-analysis including nine studies indicate that not every cytokine participating in the inflammatory reaction had a significantly altered level after probiotic supplementation. No significant difference in the IL-6 level was observed in our meta-analysis. However, we noted significant differences in the IL-8, IL-10, and TNF- $\alpha$  levels.

# 4.2. Proinflammatory Markers: IL-1 $\beta$ , IL-2, IL-4, IL-6, IL-8, TNF- $\alpha$ , and CRP

IL-1 $\beta$  is a key mediator of the inflammatory response [52] and a proinflammatory cytokine that has been implicated in inflammatory conditions [53].

IL-2 plays an immunoregulatory role; it promotes the growth and development of peripheral immune cells in the initiation of the (defensive) immune response and maintains their viability as effector cells [54].

IL-4 is associated with type 2 inflammation and can downregulate IL-1 $\beta$  and TNF- $\alpha$  because of type 1 and type 2's mutual suppression of each other [55,56].

IL-6 is a key member in the network of cytokines and plays a crucial role in acute inflammation [57]. Moreover, IL-6 exerts proinflammatory effects (e.g., in acute innate responses) and coordinates anti-inflammatory activities essential for the alleviation of inflammation [58].

IL-8 is a chemoattractant cytokine produced by various tissue and blood cells, and it attracts and activates neutrophils in inflammatory regions [59]. In addition to having chemokine properties, IL-8 acts as an angiogenic factor [60].

TNF- $\alpha$  is an inflammatory cytokine produced by macrophages and monocytes during acute inflammation and is responsible for various signaling events within cells, leading to necrosis or apoptosis [42,61].

CRP is a pentameric protein synthesized by the liver, and its level increases in response to inflammation. CRP is primarily induced by IL-6 during the acute phase of an inflammatory or infectious process [62].

Regarding proinflammatory markers, our quantitative analysis demonstrated that probiotic supplementation significantly reduced the TNF- $\alpha$  level but caused no changes in the IL-1 $\beta$ , IL-2, IL-4, IL-6, IL-8, and CRP levels. This result is consistent with that of a

previous meta-analysis investigating the effects of probiotic supplementation on normal healthy individuals and reporting a reduction in the TNF- $\alpha$  level but no differences in the IL-1 $\beta$ , IL-4, IL-6, IL-8, and IL-10 levels [63]. Although we did not observe significant changes in the levels of all proinflammatory markers in this study, their levels were lower after probiotic supplementation. In the subgroup analysis based on the timing of the postintervention blood sampling, the subgroup whose blood samples were collected immediately after exercise exhibited a significant decrease in the IL-8 level.

To perform a subgroup analysis on the basis of the period of probiotic intervention, we divided the studies into two groups: those in which athletes received probiotics for less than 6 weeks and for more than 6 weeks. The TNF- $\alpha$  level significantly changed in the shorter period group but not the longer period group, although the *p* value for the longer period group was 0.07, which is close to statistical significance. The current guidelines of the World Gastroenterology Organization indicate that it is generally not possible to state a general dose that is required for probiotics, and the dosage should be based on human studies showing a health benefit [64].

Probiotics may provide benefits by improving mucosal immunity, the inflammatory system, antioxidant capacity, stress reduction, microbiota composition, and the microenvironment in the gastrointestinal tract [65,66].

#### 4.3. Anti-Inflammatory Markers: IL-10 and IFN- $\gamma$

IL-10 is the most important cytokine with anti-inflammatory properties [67]. In terms of the correlation between the IL-10 level and exercise, the exercise-induced increase in the plasma IL-6 level is followed by increased circulating levels of anti-inflammatory cytokines, such as IL-1ra and IL-10 [35,68].

IFN- $\gamma$  coordinates a diverse array of cellular programs through transcriptional regulation of immunologically relevant genes [69]. IFN-r is considered an anti-inflammatory cytokine at low concentrations [70].

Our study revealed a reduction in the level of IL-10 but an increase in the level of IFN- $\gamma$  after probiotic supplementation in athletes. A recent systematic review on this topic reported that exercise duration is the most crucial factor determining the magnitude of the exercise-induced increase in the plasma IL-10 level. However, no significant correlation was noted between the intensity of exercise and change in the IL-10 level [71]. The appearance of IL-10 after eccentric exercise may indicate that IL-10 release is secondary to tissue damage [72]. Thus, the first reason may be the original anti-inflammatory effect of antibiotics. Since probiotics may reduce the levels of proinflammatory markers, they do not further stimulate the production of IL-10.

## 4.4. Salivary IgA

IgA is the dominant immunoglobulin isotype on all mucosal surfaces, where it acts as the first line of defense against microbial invasion [73]. It is observed that oxidative stress is the leading cause of inflammation and may have a negative impact on immune function, so curing of oxidative stress will ultimately suppress the occurrence of inflammation [74]. IgA in sublingual and submandibular secretions is a preferential noninvasive proxy for intestinal immune induction [75]. Studies have reported varying effects of exercise on the IgA level. A meta-analysis conducted in 2021 indicated that physical exercise resulted in a change in the salivary IgA level in athletes; however, this study had risk of bias and very low certainty of the evidence [76].

Our results revealed a significant increase in the salivary IgA level after probiotic supplementation in athletes, indicating that probiotics exert beneficial effects on intestinal immune function. The increase in mucosal immunity due to administration of probiotics can protect against infection from pathogens that penetrate the mucosa [43,77].

Our results demonstrate that probiotics play a role in the anti-inflammatory response; this finding is consistent with those of two previous studies reporting that probiotics exert anti-inflammatory effects in intestinal chronic diseases [78] and can prevent acute upper

respiratory tract infections [79]. The current guidelines of the American Gastroenterological Association indicate that in symptomatic children and adults with irritable bowel syndrome, the use of probiotics is recommended only in the context of a clinical trial [64]. The World Gastroenterology Organization concluded that probiotics can treat and prevent acute diarrhea but the mechanisms of action may be strain-specific [64].

#### 4.5. Heterogeneity

The results of this study had relatively high heterogeneity; the influential factors were the duration of the intervention, assessment time point, country, probiotic type, and sport type. This study evaluated multiple outcomes on the basis of different intervention and participant types. To reduce the heterogeneity in outcomes between included studies, this study conducted subgroup analyses of the characteristics of supplementation and assessments and analyzed several potential moderators.

## 4.6. Strengths and Limitations

The strength of this meta-analysis is the extensive literature search covering RCTs published over 12 years. Another advantage is that we performed subgroup analyses in relation to several potential moderators. Moreover, we analyzed several types of inflammationrelated markers.

This study has some limitations. The first is the quality of the included studies. Three of the nine studies had some concerns of bias and another study had high risk of bias; this may limit the confidence of the conclusion. In one study, fat mass was higher in the probiotic group [26]. In another study, body fat was significantly higher in the control group [20]. In one study, data were excluded due to there being insufficient blood volume to enable analyses and the loss during the follow-up was 31% [27]. In another study, one participant was excluded due to an outlier; this study had over 20% loss during followup [21]. Second, heterogeneity still existed regarding different intervention and participant types; the duration of the intervention, assessment time point, country, probiotic type, gender proportion, and sport type affected the evidence of our results. Differences between male and females included the type and intensity of physical activity. We did not review interactions related to the various species used in the supplements and if it was anticipated that there would or could be a synergistic impact on the markers. We mainly focused on probiotic supplementation and excluded studies that combined probiotics with other medications. Additionally, although we investigated the effects of probiotics on athletes, different types of sports were included, which may have resulted in different exercise intensities and thus altered the result. Finally, because the inflammation-related markers we assessed could only serve as a proxy of clinical effectiveness, the actual correlations between inflammatory markers and clinical symptoms, such as gastrointestinal syndromes and upper respiratory tract infection, were unclear.

#### 5. Conclusions

This systematic review included nine studies published from 2011 to 2022. The findings of this systematic review and meta-analysis suggest that probiotics result in significant positive changes in the levels of IFN- $\gamma$  and salivary IgA but negative changes in the levels of IL-10 and TNF- $\alpha$ , which demonstrated that probiotics play a role in the anti-inflammatory response. The levels of IL-1 $\beta$ , IL-2, IL-4, IL-6, and CRP did not exhibit significant changes. Our findings support that probiotics exert anti-inflammatory effects in intestinal chronic diseases and may be strain-specific to treat and prevent acute diarrhea. Future studies investigating the effects of probiotics can use larger samples, examine more types of exercise, and compare more types of probiotics.

Author Contributions: Conceptualization, Y.-T.G. and Y.-C.P.; methodology, Y.-T.G. and Y.-C.P.; software, Y.-T.G. and Y.-C.P.; validation, J.-C.W.; formal analysis, Y.-T.G. and Y.-C.P.; investigation, Y.-T.G.; resources, J.-C.W. and W.-H.H.; data curation, Y.-T.G. and Y.-C.P.; writing—original draft preparation, Y.-T.G., Y.-C.P. and H.-Y.Y.; writing—review and editing, W.-H.H., H.-Y.Y. and J.-C.W.; visualization, Y.-T.G.; supervision, W.-H.H.; project administration, W.-H.H.; funding acquisition, H.-Y.Y. and J.-C.W. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was supported by research grants from Taipei Medical University–Taipei Medical University Hospital (110TMU-TMUH-10 and 111TMU-TMUH-12).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

## References

- 1. Costa, R.J.S.; Snipe, R.M.J.; Kitic, C.M.; Gibson, P.R. Systematic review: Exercise-induced gastrointestinal syndrome-implications for health and intestinal disease. *Aliment. Pharmacol. Ther.* **2017**, *46*, 246–265. [CrossRef] [PubMed]
- Gleeson, M. Mucosal immunity and respiratory illness in elite athletes. Int. J. Sports Med. 2000, 21 (Suppl. 1), 33–43. [CrossRef] [PubMed]
- 3. ter Steege, R.W.; Kolkman, J.J. Review article: The pathophysiology and management of gastrointestinal symptoms during physical exercise, and the role of splanchnic blood flow. *Aliment. Pharmacol. Ther.* **2012**, *35*, 516–528. [CrossRef] [PubMed]
- 4. Lang, J.A.; Gisolfi, C.V.; Lambert, G.P. Effect of exercise intensity on active and passive glucose absorption. *Int. J. Sport Nutr. Exerc. Metab.* **2006**, *16*, 485–493. [CrossRef]
- 5. Hong, S.; Mills, P.J. Effects of an exercise challenge on mobilization and surface marker expression of monocyte subsets in individuals with normal vs. elevated blood pressure. *Brain Behav. Immun.* **2008**, *22*, 590–599. [CrossRef]
- 6. Simpson, R.J.; McFarlin, B.K.; McSporran, C.; Spielmann, G.; Hartaigh, B.O.; Guy, K. Toll-like receptor expression on classic and pro-inflammatory blood monocytes after acute exercise in humans. *Brain Behav. Immun.* **2009**, *23*, 232–239. [CrossRef]
- Shing, C.M.; Peake, J.M.; Lim, C.L.; Briskey, D.; Walsh, N.P.; Fortes, M.B.; Ahuja, K.D.; Vitetta, L. Effects of probiotics supplementation on gastrointestinal permeability, inflammation and exercise performance in the heat. *Eur. J. Appl. Physiol.* 2014, 114, 93–103. [CrossRef]
- 8. West, N.P.; Pyne, D.B.; Cripps, A.W.; Hopkins, W.G.; Eskesen, D.C.; Jairath, A.; Christophersen, C.T.; Conlon, M.A.; Fricker, P.A. Lactobacillus fermentum (PCC(R)) supplementation and gastrointestinal and respiratory-tract illness symptoms: A randomised control trial in athletes. *Nutr. J.* **2011**, *10*, 30. [CrossRef]
- 9. Nieman, D.C.; Johanssen, L.M.; Lee, J.W.; Arabatzis, K. Infectious episodes in runners before and after the Los Angeles Marathon. *J. Sports Med. Phys. Fit.* **1990**, *30*, 316–328.
- 10. Peters, E.M.; Goetzsche, J.M.; Grobbelaar, B.G.; Noakes, T.D. Vitamin C supplementation reduces the incidence of postrace symptoms of upper-respiratory-tract infection in ultramarathon runners. *Am. J. Clin. Nutr.* **1993**, *57*, 170–174. [CrossRef]
- 11. Foster, C. Monitoring training in athletes with reference to overtraining syndrome. *Med. Sci. Sports Exerc.* **1998**, *30*, 1164–1168. [CrossRef]
- 12. Mackinnon, L.T. Chronic exercise training effects on immune function. Med. Sci. Sports Exerc. 2000, 32, S369–S376. [CrossRef]
- 13. Yasmin, A.; Butt, M.S.; Afzaal, M.; van Baak, M.; Nadeem, M.T.; Shahid, M.Z. Prebiotics, gut microbiota and metabolic risks: Unveiling the relationship. *J. Funct. Foods* **2015**, *17*, 189–201. [CrossRef]
- 14. de Vrese, M.; Schrezenmeir, J. Probiotics, prebiotics, and synbiotics. Adv. Biochem. Eng. Biotechnol. 2008, 111, 1–66. [CrossRef]
- 15. Hill, C.; Guarner, F.; Reid, G.; Gibson, G.R.; Merenstein, D.J.; Pot, B.; Morelli, L.; Canani, R.B.; Flint, H.J.; Salminen, S.; et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat. Rev. Gastroenterol. Hepatol.* **2014**, *11*, 506–514. [CrossRef]
- 16. Weichselbaum, E. Potential benefits of probiotics-main findings of an in-depth review. *Br. J. Community Nurs.* **2010**, *15*, 110–114. [CrossRef]
- 17. Gibson, G.R.; Roberfroid, M.B. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. *J. Nutr.* **1995**, *125*, 1401–1412. [CrossRef]
- 18. Ouwehand, A.C.; Kirjavainen, P.V.; Grönlund, M.M.; Isolauri, E.; Salminen, S.J. Adhesion of probiotic micro-organisms to intestinal mucus. *Int. Dairy J.* **1999**, *9*, 623–630. [CrossRef]
- 19. Bernet, M.F.; Brassart, D.; Neeser, J.R.; Servin, A.L. Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions. *Appl. Environ. Microbiol.* **1993**, *59*, 4121–4128. [CrossRef]
- 20. Schreiber, C.; Tamir, S.; Golan, R.; Weinstein, A.; Weinstein, Y. The effect of probiotic supplementation on performance, inflammatory markers and gastro-intestinal symptoms in elite road cyclists. *J. Int. Soc. Sports Nutr.* **2021**, *18*, 36. [CrossRef]
- Tavares-Silva, E.; Caris, A.V.; Santos, S.A.; Ravacci, G.R.; Thomatieli-Santos, R.V. Effect of Multi-Strain Probiotic Supplementation on URTI Symptoms and Cytokine Production by Monocytes after a Marathon Race: A Randomized, Double-Blind, Placebo Study. *Nutrients* 2021, *13*, 1478. [CrossRef]

- Smarkusz-Zarzecka, J.; Ostrowska, L.; Leszczynska, J.; Orywal, K.; Cwalina, U.; Pogodzinski, D. Analysis of the Impact of a Multi-Strain Probiotic on Body Composition and Cardiorespiratory Fitness in Long-Distance Runners. *Nutrients* 2020, 12, 3758. [CrossRef]
- 23. Pugh, J.N.; Sparks, A.S.; Doran, D.A.; Fleming, S.C.; Langan-Evans, C.; Kirk, B.; Fearn, R.; Morton, J.P.; Close, G.L. Four weeks of probiotic supplementation reduces GI symptoms during a marathon race. *Eur. J. Appl. Physiol.* **2019**, 119, 1491–1501. [CrossRef]
- Quero, C.D.; Manonelles, P.; Fernandez, M.; Abellan-Aynes, O.; Lopez-Plaza, D.; Andreu-Caravaca, L.; Hinchado, M.D.; Galvez, I.; Ortega, E. Differential Health Effects on Inflammatory, Immunological and Stress Parameters in Professional Soccer Players and Sedentary Individuals after Consuming a Synbiotic. A Triple-Blinded, Randomized, Placebo-Controlled Pilot Study. *Nutrients* 2021, 13, 1321. [CrossRef]
- Quero-Calero, C.D.; Abellan-Aynes, O.; Manonelles, P.; Ortega, E. The Consumption of a Synbiotic Does Not Affect the Immune, Inflammatory, and Sympathovagal Parameters in Athletes and Sedentary Individuals: A Triple-Blinded, Randomized, Place-bo-Controlled Pilot Study. Int. J. Environ. Res. Public Health 2022, 19, 3421. [CrossRef]
- 26. Batatinha, H.; Tavares-Silva, E.; Leite, G.S.F.; Resende, A.S.; Albuquerque, J.A.T.; Arslanian, C.; Fock, R.A.; Lancha, A.H., Jr.; Lira, F.S.; Kruger, K.; et al. Probiotic supplementation in marathonists and its impact on lymphocyte population and function after a marathon: A randomized placebo-controlled double-blind study. *Sci. Rep.* 2020, *10*, 18777. [CrossRef]
- Gleeson, M.; Bishop, N.C.; Oliveira, M.; Tauler, P. Daily probiotic's (Lactobacillus casei Shirota) reduction of infection incidence in athletes. *Int. J. Sport Nutr. Exerc. Metab.* 2011, 21, 55–64. [CrossRef]
- 28. Petersen, A.M.; Pedersen, B.K. The anti-inflammatory effect of exercise. J. Appl. Physiol. 2005, 98, 1154–1162. [CrossRef] [PubMed]
- Akira, S.; Kishimoto, T. IL-6 and NF-IL6 in acute-phase response and viral infection. *Immunol. Rev.* 1992, 127, 25–50. [CrossRef] [PubMed]
- 30. Akira, S.; Taga, T.; Kishimoto, T. Interleukin-6 in biology and medicine. Adv. Immunol. 1993, 54, 1–78. [CrossRef] [PubMed]
- McCarthy, J.; O'Mahony, L.; O'Callaghan, L.; Sheil, B.; Vaughan, E.E.; Fitzsimons, N.; Fitzgibbon, J.; O'Sullivan, G.C.; Kiely, B.; Collins, J.K.; et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. *Gut* 2003, 52, 975–980. [CrossRef]
- Li, A.; Wang, Y.; Li, Z.; Qamar, H.; Mehmood, K.; Zhang, L.; Liu, J.; Zhang, H.; Li, J. Probiotics isolated from yaks improves the growth performance, antioxidant activity, and cytokines related to immunity and inflammation in mice. *Microb. Cell Fact.* 2019, 18, 112. [CrossRef]
- Hajifaraji, M.; Jahanjou, F.; Abbasalizadeh, F.; Aghamohammadzadeh, N.; Abbasi, M.M.; Dolatkhah, N. Effect of probiotic supplements in women with gestational diabetes mellitus on inflammation and oxidative stress biomarkers: A randomized clinical trial. *Asia Pac. J. Clin. Nutr.* 2018, 27, 581–591. [CrossRef]
- 34. Cytokines in the balance. Nat. Immunol. 2019, 20, 1557. [CrossRef]
- Ostrowski, K.; Rohde, T.; Asp, S.; Schjerling, P.; Pedersen, B.K. Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans. J. Physiol. 1999, 515, 287–291. [CrossRef]
- 36. Fajgenbaum, D.C.; June, C.H. Cytokine Storm. N. Engl. J. Med. 2020, 383, 2255–2273. [CrossRef]
- 37. Bernecker, C.; Scherr, J.; Schinner, S.; Braun, S.; Scherbaum, W.A.; Halle, M. Evidence for an exercise induced increase of TNF-alpha and IL-6 in marathon runners. *Scand. J. Med. Sci. Sports* **2013**, *23*, 207–214. [CrossRef]
- Cerqueira, E.; Marinho, D.A.; Neiva, H.P.; Lourenco, O. Inflammatory Effects of High and Moderate Intensity Exercise-A Systematic Review. *Front. Physiol.* 2019, 10, 1550. [CrossRef]
- Malek, T.R. The main function of IL-2 is to promote the development of T regulatory cells. J. Leukoc. Biol. 2003, 74, 961–965. [CrossRef]
- Bao, K.; Reinhardt, R.L. The differential expression of IL-4 and IL-13 and its impact on type-2 immunity. *Cytokine* 2015, 75, 25–37. [CrossRef]
- Alves, M.D.J.; Silva, D.D.S.; Pereira, E.V.M.; Pereira, D.D.; de Sousa Fernandes, M.S.; Santos, D.F.C.; Oliveira, D.P.M.; Vieira-Souza, L.M.; Aidar, F.J.; de Souza, R.F. Changes in Cytokines Concentration Following Long-Distance Running: A Systematic Review and Meta-Analysis. *Front. Physiol.* 2022, 13, 838069. [CrossRef]
- 42. Smyth, M.J.; Johnstone, R.W. Role of TNF in lymphocyte-mediated cytotoxicity. Microsc. Res. Tech. 2000, 50, 196–208. [CrossRef]
- 43. Neville, V.; Gleeson, M.; Folland, J.P. Salivary IgA as a risk factor for upper respiratory infections in elite professional athletes. *Med. Sci. Sports Exerc.* **2008**, *40*, 1228–1236. [CrossRef] [PubMed]
- 44. Harbige, L.S.; Pinto, E.; Allgrove, J.; Thomas, L.V. Immune Response of Healthy Adults to the Ingested Probiotic Lactobacillus casei Shirota. *Scand. J. Immunol.* **2016**, *84*, 353–364. [CrossRef]
- Gill, S.K.; Allerton, D.M.; Ansley-Robson, P.; Hemmings, K.; Cox, M.; Costa, R.J. Does Short-Term High Dose Probiotic Supplementation Containing Lactobacillus casei Attenuate Exertional-Heat Stress Induced Endotoxaemia and Cytokinaemia? *Int. J. Sport Nutr. Exerc. Metab.* 2016, 26, 268–275. [CrossRef]
- 46. Rohatgi, A. Webplotdigitizer, Version 4.4. 2020. Available online: https://automeris.io/WebPlotDigitizer (accessed on 3 November 2020).
- 47. Sterne, J.A.C.; Savovic, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.; Eldridge, S.M.; et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. *BMJ* **2019**, *366*, 14898. [CrossRef]
- Song, F.; Khan, K.S.; Dinnes, J.; Sutton, A.J. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. *Int. J. Epidemiol.* 2002, 31, 88–95. [CrossRef]

- 49. Cuijpers, P. 3.16—Systematic Reviews and Meta-Analytic Methods in Clinical Psychology. In *Comprehensive Clinical Psychology*, 2nd ed.; Asmundson, G.J.G., Ed.; Elsevier: Oxford, UK, 2022; pp. 224–237. [CrossRef]
- 50. Huang, W.C.; Wei, C.C.; Huang, C.C.; Chen, W.L.; Huang, H.Y. The Beneficial Effects of Lactobacillus plantarum PS128 on High-Intensity, Exercise-Induced Oxidative Stress, Inflammation, and Performance in Triathletes. *Nutrients* **2019**, *11*, 353. [CrossRef]
- 51. Moreira, A.; Delgado, L.; Moreira, P.; Haahtela, T. Does exercise increase the risk of upper respiratory tract infections? *Br. Med. Bull.* **2009**, *90*, 111–131. [CrossRef]
- 52. Lopez-Castejon, G.; Brough, D. Understanding the mechanism of IL-1beta secretion. *Cytokine Growth Factor Rev.* 2011, 22, 189–195. [CrossRef]
- 53. Ren, K.; Torres, R. Role of interleukin-1beta during pain and inflammation. Brain Res. Rev. 2009, 60, 57-64. [CrossRef]
- 54. Dembic, Z. Chapter 6—Cytokines of the Immune System: Interleukins. In *The Cytokines of the Immune System*; Dembic, Z., Ed.; Academic Press: Amsterdam, The Netherlands, 2015; pp. 143–239. [CrossRef]
- Suzuki, K.; Yamada, M.; Kurakake, S.; Okamura, N.; Yamaya, K.; Liu, Q.; Kudoh, S.; Kowatari, K.; Nakaji, S.; Sugawara, K. Circulating cytokines and hormones with immunosuppressive but neutrophil-priming potentials rise after endurance exercise in humans. *Eur. J. Appl. Physiol.* 2000, *81*, 281–287. [CrossRef]
- 56. Ma, Q. Polarization of Immune Cells in the Pathologic Response to Inhaled Particulates. Front. Immunol. 2020, 11, 1060. [CrossRef]
- 57. Zhang, C.; Wu, Z.; Li, J.W.; Zhao, H.; Wang, G.Q. Cytokine release syndrome in severe COVID-19: Interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. *Int. J. Antimicrob. Agents* **2020**, *55*, 105954. [CrossRef]
- 58. Hunter, C.A.; Jones, S.A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 2015, 16, 448–457. [CrossRef]
- 59. Bickel, M. The role of interleukin-8 in inflammation and mechanisms of regulation. *J. Periodontol.* **1993**, *64*, 456–460.
- Heidemann, J.; Ogawa, H.; Dwinell, M.B.; Rafiee, P.; Maaser, C.; Gockel, H.R.; Otterson, M.F.; Ota, D.M.; Lugering, N.; Domschke, W.; et al. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J. Biol. Chem. 2003, 278, 8508–8515. [CrossRef]
- Idriss, H.T.; Naismith, J.H. TNF alpha and the TNF receptor superfamily: Structure-function relationship(s). *Microsc. Res. Tech.* 2000, 50, 184–195. [CrossRef]
- 62. Nehring, S.M.; Goyal, A.; Patel, B.C. C Reactive Protein; StatPearls: Treasure Island, FL, USA, 2022.
- 63. Kazemi, A.; Soltani, S.; Ghorabi, S.; Keshtkar, A.; Daneshzad, E.; Nasri, F.; Mazloomi, S.M. Effect of probiotic and synbiotic supplementation on inflammatory markers in health and disease status: A systematic review and meta-analysis of clinical trials. *Clin. Nutr.* **2020**, *39*, 789–819. [CrossRef]
- 64. Su, G.L.; Ko, C.W.; Bercik, P.; Falck-Ytter, Y.; Sultan, S.; Weizman, A.V.; Morgan, R.L. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. *Gastroenterology* **2020**, *159*, 697–705. [CrossRef]
- 65. Sivamaruthi, B.S.; Kesika, P.; Chaiyasut, C. Effect of Probiotics Supplementations on Health Status of Athletes. *Int. J. Environ. Res. Public Health* **2019**, *16*, 4469. [CrossRef]
- Leite, G.S.F.; Resende Master Student, A.S.; West, N.P.; Lancha, A.H., Jr. Probiotics and sports: A new magic bullet? *Nutrition* 2019, 60, 152–160. [CrossRef]
- 67. Sabat, R.; Grutz, G.; Warszawska, K.; Kirsch, S.; Witte, E.; Wolk, K.; Geginat, J. Biology of interleukin-10. *Cytokine Growth Factor Rev.* **2010**, *21*, 331–344. [CrossRef]
- 68. Ostrowski, K.; Schjerling, P.; Pedersen, B.K. Physical activity and plasma interleukin-6 in humans–effect of intensity of exercise. *Eur. J. Appl. Physiol.* **2000**, *83*, 512–515. [CrossRef]
- 69. Schroder, K.; Hertzog, P.J.; Ravasi, T.; Hume, D.A. Interferon-gamma: An overview of signals, mechanisms and functions. *J. Leukoc. Biol.* 2004, 75, 163–189. [CrossRef]
- 70. Flaishon, L.; Topilski, I.; Shoseyov, D.; Hershkoviz, R.; Fireman, E.; Levo, Y.; Marmor, S.; Shachar, I. Cutting edge: Antiinflammatory properties of low levels of IFN-gamma. *J. Immunol.* **2002**, *168*, 3707–3711. [CrossRef]
- Cabral-Santos, C.; de Lima Junior, E.A.; Fernandes, I.; Pinto, R.Z.; Rosa-Neto, J.C.; Bishop, N.C.; Lira, F.S. Interleukin-10 responses from acute exercise in healthy subjects: A systematic review. J. Cell. Physiol. 2019, 234, 9956–9965. [CrossRef]
- Moldoveanu, A.I.; Shephard, R.J.; Shek, P.N. The cytokine response to physical activity and training. *Sports Med.* 2001, 31, 115–144. [CrossRef]
- 73. Miletic, I.D.; Schiffman, S.S.; Miletic, V.D.; Sattely-Miller, E.A. Salivary IgA secretion rate in young and elderly persons. *Physiol. Behav.* **1996**, *60*, 243–248. [CrossRef]
- Baralic, I.; Andjelkovic, M.; Djordjevic, B.; Dikic, N.; Radivojevic, N.; Suzin-Zivkovic, V.; Radojevic-Skodric, S.; Pejic, S. Effect of Astaxanthin Supplementation on Salivary IgA, Oxidative Stress, and Inflammation in Young Soccer Players. *Evid Based Complement. Altern. Med.* 2015, 2015, 783761. [CrossRef]
- Aase, A.; Sommerfelt, H.; Petersen, L.B.; Bolstad, M.; Cox, R.J.; Langeland, N.; Guttormsen, A.B.; Steinsland, H.; Skrede, S.; Brandtzaeg, P. Salivary IgA from the sublingual compartment as a novel noninvasive proxy for intestinal immune induction. *Mucosal Immunol.* 2016, *9*, 884–893. [CrossRef] [PubMed]
- Castilho, T.; da Silva Guimarães, L.; Póvoa, H.C.C.; Antunes, L.S.; Antunes, L.A.A. Influence of physical exercises on salivary immunoglobulin A (sIgA) concentration in athletes: A systematic review with meta-analysis. *Sport Sci. Health* 2021. [CrossRef]
- Clancy, R.L.; Gleeson, M.; Cox, A.; Callister, R.; Dorrington, M.; D'Este, C.; Pang, G.; Pyne, D.; Fricker, P.; Henriksson, A. Reversal in fatigued athletes of a defect in interferon gamma secretion after administration of Lactobacillus acidophilus. *Br. J. Sports Med.* 2006, 40, 351–354. [CrossRef]

- 78. Plaza-Diaz, J.; Ruiz-Ojeda, F.J.; Vilchez-Padial, L.M.; Gil, A. Evidence of the Anti-Inflammatory Effects of Probiotics and Synbiotics in Intestinal Chronic Diseases. *Nutrients* **2017**, *9*, 555. [CrossRef] [PubMed]
- 79. Hao, Q.; Dong, B.R.; Wu, T. Probiotics for preventing acute upper respiratory tract infections. *Cochrane Database Syst. Rev.* **2015**. [CrossRef]